Hyponatremia, volume status and blood pressure following aneurysmal subarachnoid hemorrhage by Wijdicks, E.F.M. (Eelco)
HYPONATREMIA, VOLUME STATUS AND 
BLOOD PRESSURE FOLLOWING 
ANEURYSMAL SUBARACHNOID HEMORRHAGE 
HYPONATRIEMIE, VOLUMESTATUS EN BLOEDDRUK NA EEN SUBARACHNOIDALE 
BLOEDll\fG DOOR EEN ANEURYSMA 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR 
AAN DE ERASMUS UNIVERSITEIT ROTTERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. A.H.G. RINNOOY KAN 
EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. 
DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP 
WOENSDAG 18 FEBRUARI 1987 TE 15.45 UUR 
DOOR 
EELCO FRANCISCUS MARIA WIJDICKS 
GEBOREN TE LEIDEI\' 
1987 
OFFSETDRUKKERIJ J.H. PASMANS B.V., 's-GRAVENHAGE 
Promotiecommissie: 
Promotor: 
Promotor: 
Overige leden: 
Prof. Dr. A Staal 
Prof. Dr.]. van Gijn 
Prof. Dr. H. var~. Crevel 
Prof. Dr. C.J.J. Avezaat 
From the department of Neurology, University Hospital Dijkzigt Rotterdam. 
"It must be recognised that one is not treating the disease of 
subarachnoid haemorrhage but a selection of surviving 
patients with that disorder." 
Michael Briggs (16) 
Aan Bar, Coenen Marilou 
Aan de nagedachtenis van mijn ouders 
4 
CONTENTS 
General Introduction 
CHAPTER I 
part 1: 
part 2: 
part 3: 
part 4: 
CHAPTER II 
CHAPTER III 
CHAPTER IV 
CHAPTER V 
Natural history and complications after subarach-
noid hemorrhage 
Aneurysmal subarachnoid hemorrhage 
Neurological complications 
Medical complications 
Hyponatremia, SIADH and regulation of sodium 
balance 
Hyponatremia and cerebral infarction. Is fluid 
restriction harmful? 
Volume depletion and natriuresis 
The effect of antihypertensive treatment 
Enlargement of the third ventricle and hypo-
natremia 
CHAPTER VI Digoxin-like immunoreactive substance 
CHAPTER VII The effect of fludrocortisone acetate on plasma 
volume and natriuresis 
General Discussion 
Summary 
Samenvatting 
References 
Scientific papers on SAH by the SAH Study Group 
Acknowledgements 
Curriculum vitae 
5 
7 
7 
9 
ll 
14 
19 
25 
39 
49 
59 
67 
77 
81 
87 
93 
100 
102 
103 
5 
GENERAL INTRODUCTION 
Patients who survive an aneurysmal subarachnoid hemorrhage (SAH) are 
endangered by complications, which especially occur during the first weeks 
after the hemorrhage. These complications have a high mortality and 
morbidity, and the outcome of patients with SAH will improve if these 
complications can be prevented or if the neurological deterioration caused by 
these complications can be reversed. To achieve this, it is of the utmost 
importance to distinguish between the different causes of deterioration after 
SAH. For instance, if a patient has an impaired level of consciousness a few 
days after the initial hemorrhage, while there were no abnormalities during 
the days before, this patient might have had a rebleed, cerebral ischemia, 
hydrocephalus or other, less common complications. 
In our department all such patients were under continuous observation in 
an intensive care unit. If a deterioration had occurred, the time course was 
documented, the patient was examined and a CT scan was repeated. The 
serum sodium levels were also measured in these patients, since it is known 
that hyponatremia may occur after SAH and can lead to neurological 
deficits. A low serum sodium level never appeared to be the direct cause of a 
deterioration, probably because the sodium levels decreased gradually and 
were never under 120 mmol/liter. However, we had the impression that 
patients with hyponatremia did worse than others. 
I decided to investigate whether SAH patients with hyponatremia did 
indeed have a particularly poor outcome, how and why hyponatremia de-
velops and how it can be prevented. These questions are the subject of this 
thesis. 
Chaper I reviews the natural history and complications after a sub-
arachnoid hemorrhage. Aneurysmal subarachnoid hemorrhage is a life-
threatening disorder with an incidence of between ll and 19 per 100,000 in-
habitants per year. The neurological complications are discussed in part 2 
and the medical complications, of which cardiac abnormalities, pulmonary 
edema and hyponatremia are the most important, in part 3. Part 4 is 
dedicated to the regulation of body water, sodium homeostasis, and the 
pathogenesis of hyponatremia. Initially it was thought that hyponatremia 
after SAH was caused by excessive sodium loss in the urine, accompanied by 
hypovolemia. This was termed cerebral salt wasting. Later, hyponatremia 
was attributed to the inappropriate secretion of antidiuretic hormone, 
causing expansion of the intravascular volume. 
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The cause of poor outcome in patients who developed hyponatremia was 
studied in a consecutive series of 134 patients with SAH. The results of this 
study are described in Chapter II. 
An important question was whether hyponatremia following subarachnoid 
hemorrhage was caused by primary salt wasting, resulting in a decrease in 
plasma volume, or by a dilution as a result of volume expansion, caused by 
inappropriate secretion of antidiuretic hormone. To elucidate the cause of 
hyponatremia a prospective study on plasma volume, sodium balance and 
secretion of antidiuretic hormone was done (Chapter III). 
Cerebral ischemia after SAH may be reversed by volume expansion and 
induced hypertension. Induced hypertension is probably effective because it 
increases cerebral perfusion pressure, resulting in improved blood flow in 
regions with ischemia. However, this treatment might be dangerous in 
patients in whom the aneurysm is still unoperated, as hypertension might 
increase the chance of rebleeding. I investigated in a large and consecutive 
series of patients whether the level of blood pressure or the institution of 
antihypertensive treatment was related to the incidence of cerebral ischemia 
and rebleeding. In addition, the relationship between antihypertensive 
treatment and cerebral ischemia was studied after adjustment for other 
factors that predispose to cerebral ischemia (Chapter IV). 
Recently, it was demonstrated that an association exists between acute 
hydrocephalus and the development of hyponatremia. It has been suggested 
that the key event is enlargement of the third ventricle which would interfere 
with hypothalamic function. I investigated if the development of hyponatre-
mia was related to enlargement of the third ventricle on the admission CT 
scan in a consecutive series of 133 patients who were seen within 72 hours of 
aneurysmal hemorrhage (Chapter V). 
Before the description of the syndrome of inappropriate secretion of 
antidiuretic hormone, hyponatremia after SAH was attributed to a putative 
natriuretic factor. An endogenous substance cross-reacting with antibodies to 
digoxin has been demonstrated in patients with hypertension, renal failure or 
atrial arrhythmias, in newborn infants, and after fluid and salt loading. This 
substance appeared to have natriuretic properties. By means of a radio-
immunoassay, plasma digoxin was measured in 25 patients with SAH not 
receiving digoxin therapy. The results of this part of the study are described 
in Chapter VI. 
A final question was whether patients who are at risk of developing volume 
depletion and natriuresis benefit from treatment with fludrocortisone 
acetate. Fludrocortisone acetate has a mineralo-corticoid action and there-
fore enhances sodium absorption. This was studied in a consecutive series of 
21 patients with SAH treated with fludrocortisone acetate and large fluid 
intake. I aimed to define the effect of this regimen on sodium balance and 
plasma volume, and at the same time to study the possible complications 
(Chapter VII). 
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Chapter I 
NATURAL HISTORY AND COMPLICATIONS 
AFTER SUBARACHNOID HEMORRHAGE 
Part 1 
ANEURYSMAL SUBARACHNOID HEMORRHAGE 
The most common cause of subarachnoid hemorrhage is rupture of a saccular 
aneurysm of the circle ofWillis. Its annual incidence lies between 11 and 19 
per 100,000 (14, 37, 92, 96). Aneurysmal rupture is extremely uncommon in 
the first decade of life. The incidence gradually increases for each decade and 
peaks in the sixth decade (92). 
As a result of the initial rupture, about one third of the patients die or 
become severely disabled, and of the remaining patients, another half will die 
or become disabled as a result of rebleeding, cerebral infarcts, and medical or 
surgical complications (52, 54, 62, 71 ). As a result, only one third of the 
patients who suffer an aneurysmal subarachnoid hemorrhage will survive 
without major disability. Even then, despite the lack of overt neurological 
deficits, these patients may have severe cognitive incapacities (107). These 
figures show that aneurysmal subarachnoid hemorrhage is a catastrophic 
event from which only few patients recover without sequelae. Unfortunately, 
the prognosis has hardly improved for many years, despite medical and 
surgical advances (126). This is largely explained by the high morbidity and 
mortality within the first 24 hours followiqg the initial hemorrhage, which is 
difficult to influence. Early death (within 24 hours of admission) is caused in 
most patients by an intracerebral hematoma, intraventricular hemorrhage 
or both. A small proportion of the patients who died from the initial 
hemorrhage might perhaps have been saved by resuscitation as they had only 
subarachnoid blood on CT, although secondary brain damage caused by 
hypoxia cannot explain death in similar patients with rebleeding who are 
resuscitated in hospital (55). 
The majority of the patients who die early can be saved only if earlier 
warning bleeds occur and if these are recognized. It has been suggested that 
massive destructive hemorrhages are preceded by minor ones. Recognition of 
these minor warning bleeds might improve the outcome following SAH (30). 
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CLINICAL PRESENTATION AND DIAGNOSTIC INVESTIGATIONS 
The clinical syndrome of SAH is marked by a sudden onset of headache, 
overwhelming in intensity, generalized or sometimes more located in the 
neck. It may be accompanied by a brief loss of consciousness, but half of the 
patients remain alert (136). Nuchal rigidity is almost always present but takes 
time to develop in the first hours after the ictus. These signs and symptoms 
may be associated with transient neurological deficits or a third-nerve palsy. 
Preretinal hemorrhage is a classic sign but may not immediately appear after 
SAH and is present in only 20% of the patients (1). 
When admitted, every patient with suspected SAH should undergo CT scan-
ning as a first investigation. CT may confirm the diagnosis by showing blood 
at the classical aneurysm sites in the basal cisterns or interhemispheric fissure 
(86). CT evidence of blood in the basal cisterns almost certainly indicates a 
ruptured aneurysm (130). Even five days after the onset, blood in the basal 
cisterns or fissures is still present in 85% of the patients. After that time, it 
rapidly clears from the basal cisterns and even intracerebral hematomas are 
no longer present after three weeks (132). CT may show other causes of 
bleeding than a ruptured aneurysm and readily shows the presence of acute 
hydrocephalus which might have immediate therapeutic implications (131, 
133). 
Recently, a non-aneurysmal and benign form of subarachnoid hemor-
rhage has been reported. On early CT, blood was seen mainly or only in the 
cisterns around the midbrain (133). The cause of this hemorrhage is not 
known, but a venous or capillary source seems likely. 
Only when CT fails to ascertain the presence of subarachnoid blood, spinal 
fluid must be obtained. However, bloody spinal fluid can be confused with a 
traumatic puncture, even by experienced neurologists. Spectrophotome-
tric screening of the supernatant must be carried out. Only if no bilirubin 
can be detected, twelve hours or more after the hemorrhage, subarachnoid 
hemorrhage can be ruled out. Conversely, the presence ofbilirubin in spinal 
fluid is highly indicative of subarachnoid hemorrhage, but cannot definitely 
distinguish between a traumatic tap and a subarachnoid hemorrhage. CSF 
cytology can be of additional value, but only if erythrophages can be demon-
strated. Negative CSF cytology cannot exclude the presence of subarachnoid 
blood (18). 
Four-vessel angiography to demonstrate the aneurysm is necessary if 
surgery is to be undertaken. With a good technique and adequate projec-
tions, a false-negative rate ofless than 2% can be achieved, irrespective of the 
presence of vasospasm (38). 
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Part 2 
NEUROLOGICAL COMPLICATONS 
Following the initial hemorrhage patients may deteriorate from many 
causes. Rebleeding and cerebral infarction are the leading causes of 
morbidity and mortality. 
The incidence of rebleeding has been overestimated in the past (58, 76, 129, 
137). In a prospective CT -scan study on episodes of acute clinical 
deterioration, rebleeding could be confirmed in 68%; other causes were 
epilepsy, acute onset of ischemia and ventricular fibrillation. In 16%, the 
acute events remained unexplained. In a series of 176 patients who survived 
the first 24 hours, the incidence of rebleeding was 22% (58). Rebleeding has a 
mortality of 56%. The overall outcome of patients who rebled is poor: 82% 
had died within three months (136). The clinical features on admission and 
the severity of the initial hemorrhage on CT are not correlated with the 
incidence of rebleeding. The peak time for rebleeding of the patients who 
survived the first 24 hours is in the second and at the end of the third week. 
When patients are included who died within 24 hours, there is a peak 
incidence on the first day (58). 
Fibrinolysis of the clot surrounding the ruptured aneurysm is an important 
factor in the pathogenesis of rebleeding, as antifibrinolytic treatment con-
siderably decreases the incidence of rebleeding ( 136). Patients at a high risk of 
rebleeding cannot be identified by clinical or radiological features on 
admission (58), nor by measuring fibrin degradation products (FDP), since 
FDP's reflect a damaged blood-brain barrier rather than fibrinolytic activity 
in the CSF (139). 
Rebleeding can be prevented by clipping of the aneurysm. The mortality 
and morbidity of this operation has considerably decreased during the last 
decades, thanks to microsurgical techniques. The timing of surgery and the 
selection of patients are points of major controversy. Some neurosurgeons 
operate on all patients within three days after the initial hemorrhage, 
irrespective of the neurological condition of the patients (117). Others delay 
operation at least two weeks and never operate on patients with an impaired 
level of consciousness (84), while other neurosurgeons prefer to operate on 
days 7-9 (121). 
Antifibrinolytic agents decrease the incidence of rebleeding (136). However, 
the outcome of patients treated with antifibrinolytics did not improve by a 
concomitant increase in the incidence of cerebral infarcts. 
Cerebral infarcts after SAH differ from atherosclerotic brain infarcts. In 
atherosclerotic brain infarcts, the clinical signs and symptoms have an acute 
onset, consciousness is rarely impaired, ischemia is confined to a single 
arterial territory, and the cause is in most cases thrombo-embolism from 
extracranial arteries or the heart. 
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Cerebral ischemia after SAH develops gradually, and approximately 75% of 
the patients have an impaired level of consciousness. Most patients have focal 
deficits, but a gradually developing decrease in consciousness can be the only 
sign. In the majority of patients with cerebral ischemia, the lesions are 
multifocal or diffuse, mainly in cortical areas and boundary zones (57). 
This type of lesion may be caused by arterial spasm, as spasm can be 
multivascular or even generalized. It is unlikely that vasospasm is the only 
factor that leads to cerebral ischemia, since more than half of the patients 
with ruptured aneurysms have angiographic evidence of vasospasm, whereas 
about 27% of all patients develop clinical signs and symptoms of cerebral 
ischemia (2). 
Other factors such as brain swelling, acute hydrocephalus, increased intra-
cranial pressure and hemoconcentration may also impair cerebral perfusion. 
The peak incidence of ischemia occurs within four to ten days of the initial 
hemorrhage (53, 57, 71, 105). When clinical signs of cerebral ischemia 
appear, the prognosis is poor. Thirty-seven per cent of the patients with 
cerebral infarcts die from brain swelling with herniation. Patients who 
survive a cerebral infarct may eventually die from other complications that 
occur after SAH. In a series of95 patients who had an infarct, 58% had died 
within three months of the initial hemorrhage (136). Prognostic factors for 
cerebral ischemia are the amount of subarachnoid blood on CT (65), intra-
ventricular hemorrhage and antifibrinolytic treatment (56). 
Many treatments for cerebral ischemia after SAH have been proposed. 
Improvement after volume expansion has been reported (98), induced 
hypertension might also be beneficial (17, 68), or a combination ofboth treat-
ments (63). The use of extracranial-intracranial bypass surgery might reverse 
ischemia (104). Calcium-entry blockers might prevent vasospasm or limit the 
extent of ischemia, according to one clinical trial (2), but the results were not 
convincing (138). Other clinical trials about the effectiveness of calcium-entry 
blockers are in progress. It has also been suggested that removal ofblood clots 
from the basal cisterns during an early qperation might prevent cerebral 
ischemia (80). 
The incidence of intracerebral hematomas varies from 4 to 35% (94), and 
they are associated with a high mortality (30-50%). Ruptured middle 
cerebral artery aneurysms cause an intracerebral hematoma more frequently 
than aneurysms at other sites (94, 145). Patients admitted with signs of 
brainstem compression do poorly, regardless of treatment (145). 
Acute hydrocephalus occurs in 20% of the patients admitted early after the 
hemorrhage and is in most cases associated with impaired consciousness 
(134). This incidence is higher than in a series from a neurosurgical unit 
(135), probably because many patients with acute hydrocephalus never 
reach the neurosurgeon as they are considered in too bad a condition for 
operation. 
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In patients with an impaired level of consciousness from the time of the 
hemorrhage and with enlarged ventricles on CT, the clinical signs can be a 
direct effect of the hemorrhage or of hydrocephalus. In such a situation it is 
difficult to decide whether or not a shunt should be placed. 
More specific for acute hydrocephalus is a history of gradually progressive 
impairment of consciousness within the first days of the hemorrhage, or the 
presence of small non-reactive pupils with otherwise intact brainstem reflexes 
(134). The cause of impaired consciousness in patients with acute hydroce-
phalus is probably a reduction of cerebral blood flow by the enlarged 
ventricles. This might explain why the immediate effect of shunting was 
invariably impressive. However, the outcome of patients in whom a shunt 
was placed, was poor (81, 134). Cerebral ischemia or rebleeding was the 
cause of death in most patients. It seems, however, illogical not to treat 
patients with acute hydrocephalus, as rapid improvement of cerebral blood 
flow rna y yet lessen theTisk of developing cerebral ischemia. Moreover, when 
patients remain in a state of impaired consciousness, they run an increased 
risk of extracranial complications (134). 
Seizures occur in about one quarter of the patients and may be easily 
confused with rebleeding. In one series, 63% of the seizures was observed soon 
after the initial hemorrhage (50). 
Part 3 
MEDICAL COMPLICATIONS 
Electrocardiographic abnormalities are frequently seen in association with 
aneurysmal subarachnoid hemorrhage. The incidence is estimated at 
approximately 50% (73). The most consistent ECG findings are inverted T 
waves, ST segment depression or elevation, QT prolongation and pathologi-
cal Q waves (23). Pathological Q waves bra raised ST segment indicate a 
poor prognosis (23). Diffuse myofibrillar degeneration accounts for these 
ECG changes (100). These lesions are not specific for SAH as they have been 
observed in both ischemic and hemorrhagic strokes (91 ). The lesions were 
dispersed throughout the myocardium and were not seen in areas normally 
associated with coronary artery occlusion. They were not present in patients 
suddenly dying from a violent cause, nor were they present more than two 
weeks after the acute intracranial event (67). 
The myocardial damage correlates with changes in serum cardiac 
enzymes, including cardiospecific CPK-MB. Unlike the acute rise and fall of 
serum CPK-MB levels within 36 hours seen in patients with acute myo-
cardial infarction, the enzyme levels in SAH rise gradually over the first few 
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days, reach their peak by about seven days and return to normal by the 
second week (91). It has been suggested that increased levels of catechol-
amines lead to hypertension, ventricular strain and subsequent ischemia of 
subendocardial tissues; also a direct tissue toxic effect has been proposed (20). 
Hypothalamic hemorrhages might be responsible for this increased sympa-
thetic drive (13, 29, 87). Patients with SAH might therefore benefit from /3-
blocking agents, which counteract the hyperactivity of the sympathetic 
nervous system. This was investigated in a randomized clinical trial (140). 
The mortality was not significantly different between patients treated with 
placebo or with /3- blocking agents, but this study was too small to be 
conclusive. 
Dangerous ventricular dysrhythmias which have been linked with prolon-
gation of the Q-T interval, have been found in 20% of patients following SAH 
(31). However, of all acute cardiorespiratory complications, most are 
primary disorders of respiratory rhythm and not cardiac arrhythmias. In a 
prospective series of 264 patients, only 2 patients had symptomatic cardiac 
arrhythmias (59). 
Neurogenic pulmonary edema is a dramatic and dangerous complication with 
an extremely rapid onset, although rarely a delayed course has been reported 
(34). The typical clinical picture is unexpected dyspnea, cyanosis and 
production of pink and frothy sputum. In addition, pallor, sweating and a 
rapid, weak pulse may occur. Many cases were fatal, but mortality has 
decreased especially by the introduction of positive end-expiratory pressure 
(141). Pulmonary edema is not rare; a postmortem study revealed that in 
patients with fatal SAH, 71% had pulmonary edema and of these, 31% had a 
clinical diagnosis of pulmonary edema (142). Neurogenic pulmonary edema 
might be caused by a massive sympathetic discharge, mediated by the 
hypothalamus (5). This results in a rise of systemic and pulmonary vascular 
pressure and pulmonary capillary damage. Therefore, pulmonary edema 
persists despite the return of systemic and pulmonary pressures to normal in a 
later phase (122). Pulmonary wedge pressures were found to be normal in 
these patients (49). 
Gastrointestinal bleeding in the preoperative period is rare. It may occur 
during the course of the illness in 0.02 to 3% of patients with SAH (119, 143). 
Infections and septicemia are frequently encountered. In a series of 100 
patients, 39% developed serious infections, of which 41% were caused by 
urinary infections ( 143). 
Hyperglycemia with glycosuria is a well recognized finding following 
subarachnoid hemorrhage. Abnormal glucose tolerance tests and increased 
insulin levels were found in 15 of 20 patients (48). 
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Many patients with SAH develop hypertension immediately following the 
acute event. It is therefore understandable that hypertensive encephalopathy 
is a common misdiagnosis ( 1). It is, however, difficult to make an accurate 
estimate of its incidence, because of the lack of criteria for hypertension in 
patients who are severely ill and stressed. The Cooperative Aneurysm Study 
Group (125) found that hypertension was associated with higher mortality. A 
systolic blood pressure of 170 mm Hg or more was significantly related to 
recurrent hemorrhage, a diastolic blood pressure of 100 mm Hg or more was 
not. 
In the study of Winn et al. (146) systolic hypertension was defined as 
160 mm Hg or greater and diastolic hypertension as 110 mm Hg or greater. 
They found that, at least in their series, high diastolic blood pressure was 
associated with a worse prognosis, but only in patients with an anterior com-
municating artery aneurysm; the influence on rebleeding was not mentioned. 
It is impossible to conclude from these studies how hypertension after SAH 
ought to be managed. 
Hypertension might increase the incidence of rebleeding and also of 
cerebral infarcts. Experimental studies showed that hypertension produced 
vibratory damage of the wall of the aneurysm by increased turbulence within 
the aneurysm, which damage may result in rerupture (32). Hypertension 
may also aggravate cerebral ischemia by edema formation (114). 
However, treatment of hypertension in patients with impaired autoregu-
lation can reduce cerebral blood flow as in these patients cerebral blood flow 
is dependent on arterial pressure. 
Hyponatremia is a frequent electrolyte disturbance. In a series of 290 
patients with. SAH, 10% developed hyponatremia, fulfilling laboratory 
criteria of the syndrome of inappropriate secretion of antidiuretic hormone 
(SIADH). Other causes of hyponatremia were not found. Half of the patients 
had severe hyponatremia leading to an impaired level of consciousness (27). 
Several additional case reports on SIADH in patients with SAH were 
reported in the literature (61, liS, 148). Unfortunately, all reports lack 
detailed descriptions of the deterioration which was attributed to hyponatre-
mia, nor do they provide data on sodium and fluid balances before the 
development of hyponatremia, which makes the interpretation of hypona-
tremia difficult. 
The concept of the notion of SIADH in patients with SAH merits a 
separate discussion. 
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Part4 
HYPONATREMIA, SIADH AND REGULATION OF 
SODIUM BALANCE 
REGULATION OF BODY WATER AND SODIUM HOMEOSTASIS 
The most important mechanism for the control of body water is osmo-
regulation via the antidiuretic hormone (103). In the internal carotid artery 
and probably in the hypothalamus osmoreceptors are present, which respond 
to changes in plasma osmolality. The plasma osmolality is an expression of 
the number of osmotically active particles per kilogram of water. As sodium is 
the most important osmotically active particle, plasma osmolality is prac-
tically a reflection of the serum sodium concentration. The osmoreceptors 
respond to an increase in plasma osmolality (of about 2%) by stimulating the 
neurohypophysis to secrete antidiuretic hormone, which results in reabsorp-
tion of water by the kidneys and dilution of the plasma, back to normal 
osmolality. ADH secretion may also respond to changes in intravascular 
volume (108) as a decrease in plasma volume may stimulate ADH secretion 
even though plasma osmolality is low. Other non-osmotic stimuli of ADH 
secretion are pain, stress, emotion and certain drugs (82). 
The control of sodium balance is mediated by the kidney. When function-
ing appropriately, the kidney corrects volume expansion and volume 
depletion with natriuresis and increased sodium reabsorption, respectively 
(111 ). For instance: an increase in sodium intake leads to increased water 
intake (by thirst mechanism), expansion of extracellular volume, decrease of 
renin production and decrease of the sodium retaining hormone aldosteron, 
eventually resulting in natriuresis. The kidney regulates urinary sodium 
excretion in such a way that sodium excretion eventually equals sodium 
intake and a steady state is achieved. Normally, osmoregulation and volume 
regulation work in harmony (69). 
Recently, an additional natriuretic mechanism was introduced (69, 85): 
digoxin-like substances, later followed by the discovery of a group of peptides 
from atrial tissue (atrial natriuretic hormone). 
It has been suggested that this atrial natriuretic hormone opposes the renin-
aldosteron system in situations involving high blood pressure and sodium 
surfeit (69, 85). 
FROM CEREBRAL SALT WASTING TO SIADH, A HISTORICAL REVIEW 
In 1950, Peters et al. described three patients with central nervous system 
disease (encephalitis, stroke, brainstem tumor), in whom balance studies 
revealed excessive sodium loss in the urine at the time of severe hypona-
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tremia. This was termed cerebral salt wasting syndrome (95). The hypona-
tremia could not be corrected by high salt intake or mineralocorticoid 
administration. Adrenal and pituitary function tests were normal. Clinically, 
these patients exhibited dehydration. After volume expansion, the loss of 
sodium in the urine was increased. Later, similar case histories were reported 
(21, 144). It was suggested that the most probable explanation for urinary 
sodium loss was a decreased proximal tubular reabsorption of sodium. 
After the syndrome of inappropriate antidiuretic hormone (SIADH) had 
been defined in 1957 by Bartter and Schwartz, who described it in two 
patients with bronchogenic carcinoma (11 ), cerebral salt wasting has seldom 
been reported. 
In SIADH there is a continuing secretion of ADH, not appropriate to 
changes of plasma osmolality. Because of the secretion of ADH, extracellular 
volume and intravascular volume increase. As a result of expansion of the 
intravascular volume, dilutional hyponatremia occurs. Natriuresis takes 
place because volume expansion increases the glomerular filtration rate and 
inhibits the secretion of aldosteron. Balance studies showed that natriuresis is 
small and approximately equals intake. The high urinary sodium concentra-
tion in SIADH is explained by the fact that the sodium intake must be 
excreted in a small volume of urine (II). 
The Criteria of SIADH include hyponatremia, serum hypo-osmolality, a 
urine osmolality which is higher than serum osmolality, continued urinary 
excretion of sodium in spite of hyponatremia, absence of hypovolemia, 
normal renal and adrenal functions, no diuretic medication and correction of 
hyponatremia after fluid restriction. However, the correction ofhyponatre-
mia after fluid restriction may also occur in hyponatremia from other causes 
(II, 36). 
It has been suggested that hypouricemia is of diagnostic value in patients 
with SIADH, since only these patients have low levels of serum uric acid, 
whereas normal levels were found in patients with hyponatremia of other 
causes (12). 
SIADH may occur in SAH but also in various other neurological disorders 
(70). 
Head injury with and without skull fractures 
Herpes simplex encephalitis 
Tuberculous meningitis 
Brain abscess 
Systemic lupus erythematosus 
Cerebral infarction 
Brain tumors 
Subdural hematoma 
Hydrocephalus 
Multiple sclerosis 
Central pontine myelinolysis 
Guillain-Barre syndrome 
Wernicke encephalopathy 
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Some authors think that SIADH is diagnosed too often, without a valid ba-
sis (36, 4 7). Zerbe et al. reported normal ADH levels in 80% of a group of 79 
patients with various diseases who were thought to have SIADH (150). In a 
study of 17 patients with severe hyponatremia who met the criteria of 
SIADH, high levels of ADH were found only in patients with infections or 
carcinoma of the lung (123). In a large prospective study on the causes of 
hyponatremia, plasma ADH levels in patients who met the criteria ofSIADH 
were significantly lower than in patients with hyponatremia from other 
causes (4). 
In subarachnoid hemorrhage plasma ADH levels have seldom been 
measured in patients with hyponatremia. Gupta described two patients with 
SAH and SIADH with normal plasma ADH levels ( 4 7). Mather found 
elevated plasma ADH levels in only five of nine patients with hyponatremia 
caused by SIADH (75). 
Nelson et al. (1981) further questioned the existence ofSIADH. In a study 
of 12 patients with intracranial disease (6 with SAH), 10 had decreased 
intravascular blood volumes despite fulfilling the criteria for SIADH (88). 
In a monkey model of subarachnoid hemorrhage they observed primary 
natriuresis as the cause of hyponatremia rather than SIADH (89). 
HYPONA TREMJA, CLASS/FICA TION AND DIAGNOSTIC APPROACH 
The causes of hyponatremia vary according to the patients' volume status. In 
most cases of hyponatremia the total body sodium is constant, but the water 
content of the extracellular volume is at fault (109, 111 ). 
Hyponatremia can be categorized in relation with extracellular volume 
status (109). 
I. Hyponatremia associated with diminished extracellular fluid volume 
- gastrointestinal losses 
- diuretic therapy 
- a variety of renal disorders 
- adrenal insufficiency 
II. Hyponatremia associated with modest extracellular volume excess 
- hypothyroidism 
- pain, emotion and antidiuretic drugs 
- SIADH 
III. Hyponatremia associated with profound extracellular volume excess 
- cardiac failure 
- nephrotic syndrome 
- cirrhosis 
- iatrogenic fluid loading (15) 
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Other causes of hyponatremia are pseudohyponatremia caused by hypo-
proteinemia or paraproteinemia, hyperglycemic hyponatremia and labor-
atory error (3, 4). 
CLINICAL FEATURES OF HYP.O"N:4 TREMIA 
The signs and symptoms of hyponatremia are mostly manifestations of 
disturbed CNS functions and depend upon the severity and rapidity of the 
development of hyponatremia (7). Signs and symptoms do usually not occur 
until plasma sodium is less than 125 mmol/L. In general, no predictable 
correlation exists between the degree of hyponatremia and the alteration in 
consciousness. The signs consist of impaired consciousness, apathy, ataxia, 
asterixis, hemiparesis, seizures and coma. 
MANAGEMJ!,"J\7 OF HYPO.NA TREMIA 
Many patients with moderate degrees of hyponatremia are asymptomatic. 
The therapeutic approach must be directed towards the cause of the hypo-
natremia (e.g. discontinuation of diuretics; sodium and water restriction in 
the edematous hyponatremic patient). Rapid correction of hyponatremia is 
therefore justified only when central nervous system symptomatology rapidly 
develops. 
Hyponatremia, whatever the cause, can always be corrected by infusion of 
hypertonic salt solution, but this effect is only transient because the sodium is 
rapidly excreted. 
Fluid restriction is recommended in SIADH or other causes of water intoxi-
cation. However, one should keep in mind that a careful water balance is 
needed as the patient may be pushed into rapid dehydration. Rapid decline 
of the plasma sodium under 125 mmol/liter is associated with considerable 
mortality (about 50%) and morbidity (3-15%). On the other hand, rapid 
correction of hyponatremia is associated with central pontine myelinolysis. 
Ayus et al. concluded that this condition particularly occurred in.alcoholic 
patients and that it was not related to the speed of correction of hyponatre-
mia, but probably caused by the effect of the underlying disorder (l 0). Sterns 
et al. reviewed reports on patients with very severe hyponatremia and found 
neurological sequelae to be associated with correction of hyponatremia by 
more than 12 mmol per liter per day (115). However, acute symptomatic 
hyponatremia is a medical emergency and ought to be treated with 
hypertonic NaCl at a rate of infusion such that plasma sodium is raised at a 
rate of 2 mmol/liter per hour until a serum sodium of 125 to 130 mmol is 
achieved (6, 10). Recently, good results were reported with intravenous 
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29.2% saline (149), although complications such as heart failure and 
pulmonary edema may be associated with this therapy. 
The treatment of hyponatremia in SAH is controversial. When a clinical 
deterioration in SAH occurs, together with hyponatremia, it is hard to tell 
which causes which, or whether there is a common cause. On the other hand, 
when hyponatremia occurs in a patient in good clinical condition, it is not 
known if "masterly inactivity" (36) or an aggressive approach is necessary. 
This controversy was one of the incentives for the studies reported in this 
thesis. 
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Chapter II 
HYPONATREMIA AND CEREBRAL INFARCTION. 
IS FLUID RESTRICTION HARMFUL? 
Following aneurysmal subarachnoid hemorrhage (SAH), patients are likely 
to develop hyponatremia, frequently attributed to the syndrome of in-
appropriate secretion of antidiuretic hormone (SIADH) (27, 61, 70, 129, 
148). Because the hyponatremia of SIADH is often attributed to dilution 
caused by expansion of the extracellular volume, fluid intake is usually 
restricted (11 0). 
Recently, Nelson and colleagues (88) questioned whether volume expan-
sion occurs in SIADH. It has been further suggested that fluid restriction can 
cause hypovolemia and subsequent ischemia if vasospasm is present (53, 116). 
To elucidate this problem, we studied the relationship between hypo-
natremia and cerebral infarction in patients with subarachnoid hemorrhage. 
PATIENTS AND METHODS 
We studied 134 consecutive patients with signs and symptoms of SAH and 
with computed tomographic (CT) evidence of extravasated blood in the 
basal cisterns, suggesting a ruptured aneurysm. All patients were without 
evidence of another cause of SAH (130). Patients with normal angiographic 
findings or another cause of SAH were not included in the study. 
All patients were admitted within 72 hours of the initial hemorrhage and 
took part in a randomized, double-blind, placebo-controlled trial of 
tranexamic acid (136) (65 patients were given tranexamic acid and 69 were 
given placebo). 
In 99 of the 134 patients an aneurysm was demonstrated by angiography or 
at postmortem examination. In the other 35 angiography was not performed 
because surgical treatment of the aneurysm was not considered; these 
patients fo~ whom operation was ruled out were those over 65 years of age and 
those exhibiting an impaired level of consciousness or ischemic cerebral 
deficits. 
During the study period, which lasted four weeks or until death or opera-
tion, all patients were under continuous observation in an intensive care unit. 
Most operations were carried out on the twelfth day after the presenting 
hemorrhage. 
CT scanning was performed on admission and repeated at least weekly. 
Clinical deteriorations were studied prospectively. When a patient's condi-
tion deteriorated, the patient was reexamined and the CT scan was repeated. 
Infarction was diagnosed by two criteria: (1) if a patient gradually 
developed a focal neurological deficit, with or without evidence of infarction 
on repeated CT scanning, and (2) if a gradual deterioration of consciousness 
occurred at least 1 point on the motor score of the Glasgow coma scale (120), 
with CT confirmation of ischemic changes. 
Hyponatremia was defined as a sodium level lower than 135 mmol/L on at 
least two consecutive days, in the absence ofhyperlipemia and paraproteine-
mia (conditions that may falsely suggest hyponatremia) (36). 
Serum sodium levels were measured on admission and at least three times a 
week and reviewed retrospectively. The criteria for SIADH were hypona-
tremia (as just defined), serum osmolality lower than 280 mmol/L, urine 
osmolality higher than serum osmolality, continued urinary excretion of 
sodium in spite of hyponatremia, normal findings on renal function tests 
(blood urea nitrogen, serum creatinine), and absence of hypotension or 
severe hypothyroidism (36, 42). We defined fluid restriction as an intake of 
1,000 ml or less per 24 hours. Patients with temperatures between 37 and 
38°C were considered to have a restricted fluid intake when intake fell below 
1,500 ml per 24 hours; in patients with temperatures between 38 and 39°C 
the crucial level was 1,750 ml per 24 hours. 
RESULTS 
Hyponatremia (sodium level of 120 to 134 mmol/L) developed in 44 (33%) of 
the 134 patients. It was mild (130 to l34mmol/L) in 18, moderate (125 to 129 
mmol/L) in 20, and severe (120 to 124 mmol/L) in 6. In all instances the 
hyponatremia developed between days 0 and 10 (median 4) after the 
hemorrhage. Twenty-five patients with hyponatremia fulfilled the labor-
atory criteria for SIADH (18% of 134). Twelve patients had other conditions 
that might have contributed to hyponatremia, sepsis (2 patients), severe 
vomiting (3 patients), renal disease (3 patients), Addison's disease (1 patient), 
and diuretics (3 patients). In 7 cases the cause remained unknown because of 
incomplete laboratory investigations. 
Cerebral infarction was diagnosed in 46 of the 134 patients and confirmed 
by CT scan or postmortem study in 41. Infarction occurred 2 to 24 days 
(median 9 days) after the presenting hemorrhage. 
Twenty-seven of the cerebral infarctions occurred in the 44 patients who 
developed hyponatremia, and 19 in the 90 patients who maintained normal 
sodium levels ( X2 test, p < 0.001) (Table 1). When these abnormalities 
coincided, hyponatremia always 'preceded the signs and symptoms of 
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Table I. Relationship between hyponatremia and cerebral infarction in 134 patients with 
subarachnoid hemorrhage 
No. of patients 
With Without 
Serum sodium level infarction infarction Total 
~135 mmol/L 19* 71* 90 
<135 mmoi!L 27 17 44 
Total 46 88 134 
*Significantly different from number in hyponatremic group by chi-square test (p < 0.001 ). 
cerebral infarction. Cerebral infarction occurred 2 to I4 days (mean 6 days) 
after the development of hyponatremia. 
Infarction was more often fatal in patients with hyponatremia; I2 of the 27 
infarctions in patients with hyponatremia resulted in death, in contrast to 6 of 
the I9 infarctions in patients with normal sodium levels ( x2 test, p < O.OI). 
The incidence of infarctions was higher in patiens with fluid restriction, 
with or without sufficient evidence of SIADH (Table 2) (Fisher's exact test; 
p = 0.004). Seventeen patients with SIADH were fluid restricted; of these, 15 
developed infarction. Nine patients with other causes of hyponatremia were 
fluid restricted; of these, 6 developed infarction. 
Table 2. Relationship between fluid restriction and cerebral infarction in 44 patients with 
hyponatremia. 
No. of patients 
Patients with With Without 
hyponatremia infarction infarction Total 
Fluid restricted* 21** 5** 26 
Normal fluid intake 6 12 18 
Total 27 17 44 
*See Methods section for criteria. 
**Significantly different from number in group with normal fluid intake by Fisher's exact 
test (p = 0.004). 
Tranexamic acid did not increase the incidence of hyponatremia. 
Among patients with infarction, I6 of the 27 with hyponatremia and II of the 
I9 with normal serum sodium levels were given tranexamic acid (Fisher's 
exact test; p2 = 1.0). The level of consciousness on admission did not differ in 
patients with low and with normal sodium levels. 
Of the 5 patients in whom cerebral infarction was inferred from focal signs 
without CT changes, 3 had normal sodium levels and 2 had hyponatremia. 
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Focal signs indicating cerebral infarction that developed during the course of 
hyponatremia persisted in all instances after correction of the electrolyte 
imbalance. 
DISCUSSION 
This study found the incidence of cerebral infarction after aneurysmal SAH 
to be significantly higher in patients who developed hyponatremia. Further-
more, patients with cerebral infarction and hyponatremia had a higher 
mortality than patients with cerebral infarction and normal sodium values. 
We did not find episodes of clinical deterioration that could be attributed 
to hyponatremia alone, without clinical or radiological signs of cerebral 
ischemia. This pattern may be explained by the gradual development of 
hyponatremia and by the absence of sodium levels below 120 mmol/L (7). 
The incidence of hyponatremia in our series was higher than that in the 
report ofDoczi and colleagues (27) (33% versus 9%), a difference that may be 
explained by the more frequent determinations of sodium levels in our study. 
In addition, we found causes of hyponatremia other than SIADH. 
Fluid restriction to correct hyponatremia was introduced after the 
description of the SIADH by Schwartz and co-workers (ll 0). The action of 
antidiuretic hormone is believed to lead to an expansion of extracellular 
volume. Normally, the osmotic receptors depress the secretion of antidiuretic 
hormone after expansion of the extracellular volume, but in SIADH they 
function inappropriately as a result of osmotic resetting. This leads to a 
sustained secretion of antidiuretic hormone and a further increase in the 
extracellular volume, with subsequent suppression of secretion of aldoste-
rone, hyponatremia, and natriuresis. In fact, in true SIADH, hyponatremia 
is a dilutional hyponatremia and not a true sodium depletion; therefore, fluid 
restriction is a recommended therapy (36, 42). 
In patients with SAH (27, 61, 148), an inappropriate secretion of anti-
diuretic hormone was initially thought to explain tlie hyponatremia and 
natriuresis. Zerbe and colleagues (150), however, reported normal levels of 
antidiuretic hormone, and volume expansion could not always be demon-
strated in patients with SIADH. Nelson and associates (88) even found a 
significant decrease in both plasma and total blood volume in patients who 
fulfulled the criteria for SIADH. 
Before the description ofSIADH, hyponatremia in patients with SAH was 
attributed to a natriuretic hormone that caused true sodium depletion. This 
phenomenon was termed cerebral salt wasting (21, 95), but the natriuretic 
hormone has not yet been ipentified. Nevertheless, recent evidence suggests 
that hyponatremia, after all, is caused by a true sodium loss and not by a 
dilution resulting from an increased extracellular volume (88, 89). If so, fluid 
restriction may be harmful rather than beneficiaL If our patients with 
hyponatremia had a decrease in plasma volume, as Nelson and associates (88) 
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found in their patients, fluid restriction might have aggravated a hypovolemic 
state, leading to hemoconcentration and changes in blood viscosity. Hemo-
concentration may be especially dangerous in patients with vasospasm and 
other characteristics that decrease cerebral perfusion pressure and result in 
prolonged ischemia. Hyponatremia developed between the second and the 
tenth day after the initial hemorrhage. Fluid intake was restricted in many of 
these patients at a time when they were at especially high risk of ischemic 
complications. 
Many authors insist on an adequate volume status in patients with SAH, 
and others even advise volume exp'tnsion if signs and symptoms of ischemia 
develop (53, 63, 74). Until the incidence of hyponatremia and infarction in 
patients with a normal volume status is known more precisely, we conclude 
that fluid restriction to correct hyponatremia is potentially dangerous in 
patients with aneurysmal SAH. 
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Chapter III 
VOLUME DEPLETION AND NATRIURESIS 
INTRODUCTION 
Many conditions can lead to hyponatremia, but if associated with a 
decreased serum osmolality and increased natriuresis, it is generally attrib-
uted to inappropriate secretion of antidiuretic hormone (27, 61, 11 0). In this 
syndrome, continued secretion of antidiuretic hormone results in increased 
extracellular fluid volume, increased body weight, and dilutional hypona-
tremia. Natriuresis is increased as volume expansion causes suppression of 
aldosteron, and possibly as a result of a decrease in tubular sodium 
reabsorption, but this need not necessarily result in a negative sodium 
balance (36, 11 0). 
Originally, hyponatremia in cerebral diseases was thought to be caused by 
salt wasting (21, 95). Primary loss of sodium with a concurrent loss of extra-
cellular fluid volume would result in a decrease in plasma volume and body 
weight, an increase in blood urea nitrogen, and a negative salt balance. This 
explanation was recently reintroduced (88) and indirectly supported by our 
observation that fluid restriction to correct hyponatremia in patients with 
subarachnoid hemorrhage increases the incidence of cerebral infarction 
(Chapter II). It is likely that fluid restriction impairs cerebral perfusion by 
aggravating preexisting hypovolemia. 
To elucidate the cause of hyponatremia in subarachnoid hemorrhage 
-depletion or dilution- we performed a prospective study of plasma volume, 
sodium balance, and secretion of antidiuretic hormone in these patients. 
PATIENTS AND METHODS 
Patients 
Twenty-one patients with subarachnoid hemorrhage were studied. Patients 
with signs and symptoms of subarachnoid hemorrhage and with computed 
tomographic (CT) evidence of blood in the basal cisterns suggesting a 
ruptured aneurysm, but without evidence of another cause of subarachnoid 
hemorrhage, were included (130, 133). 
All patients were admitted within 48 hours of the initial hemorrhage. 
Patients with any of the following conditions were excluded: endocrine dis-
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turbances, heart failure, renal failure, neoplasm, and treatment with diuretic 
drugs. We treated no one with diuretics, steroids, or antifibrinolytic agents. 
In 18 of the 21 patients an aneurysm was demonstrated by angiography. In 
the other 3 patients angiography was not performed; surgical treatment was 
not indicated because of age (over 70) or impaired level of consciousness. 
However, rupture of an aneurysm in these patients was considered highly 
probable because of the presence of blood in the interhemispheric, supra-
sellar, or sylvian cisterns without evidence of another lesion (130). 
During the study period, which lasted 10 days, all patients were under 
continuous observation in an intensive care unit. CT scan was performed on 
admission and repeated if a patient's clinical condition deteriorated. 
Infarction was diagnosed if a patient had gradually developed a focal 
deficit and if CT scanning showed one or more areas of hypodensity. 
Rebleeding was diagnosed if sudden deterioration occurred and if CT 
scanning showed an increased amount of blood compared with the previous 
scan (137). 
Fluid and sodium balance 
We obtained daily measurements of electrolytes, blood urea nitrogen, 
creatinine, serum osmolality, and hematocrit. Hyponatremia was defined as 
a sodum level lower than 135 mmol/L on at least two consecutive days. When 
hyponatremia occurred, we measured creatinine clearance, thyroid func-
tion, and plasma cortisol concentrations. The criteria for inappropriate 
secretion of antidiuretic hormone were hyponatremia as defined above, 
serum omolality lower than 280 mmol/L, a urine osmolality value higher 
than that of serum osmolality, continued urinary secretion of sodium in spite 
of hyponatremia, and absence of hypotension, hypothyroidism, Addison's 
disease, or renal failure (70, 110). 
All patients had a minimal fluid intake ofl ,500 ml per 24 hours. None were 
fluid restricted, even when hyponatremia occurred. 
The sodium intake was calculated from the sodium content of the food, 
which was specially prepared, and from the sodium content of the fluids that 
were given intravenously for 5 days. Sodium excretion was measured in 24-
hour urine samples. Salt balance was considered negative when sodium 
e;xcretion in the urine was larger than the daily sodium intake. Loss of sodium 
from the skin or in the feces was not included in· the calculations of sodium 
balance. 
Plasma volume determinations 
The patients studied underwent plasma volume determinations on admission 
and again on the sixth day after the initial hemorrhage or when hypo-
natremia occurred. Body weight was measured at the same time. 
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Plasma volume was determined by the isotope dilution technique with 131 I 
labeled to human serum albumin (HSA) (41). We injected intravenously 
5 mg HSA labeled with a total dose of 158 kilobecquerels 1311 in 5 ml of 
physiological saline. Blood samples were taken before injection ofthe tracer 
substance and at 8 and 13 minutes after injection. Between 8 and 13 minutes, 
a given dose is evenly distributed throughout the blood volume and there is 
no disappeareance into extravascular spaces (41). Plasma volume was 
calculated on a Gammatrac 1191 (Tracor Analytic). 
In normal subjects, plasma volume has an average value of 40 ml per kilo-
gram of body weight ( 41 ), but because most patients showed changes in body 
weight, we expressed the results in tbtal plasma volume and calculated the 
percentage of change between the first measurements and the measurements 
taken after 6 days. Because bed rest alone may cause a decrease in plasma 
volume after 1 week (45), we considered only a decrease of more than 10% to 
be substantial. 
Arginine vasopressin 
We measured serum vasopressin concentrations in 19 ofthe 21 patients. The 
patients studied were selected for practical reasons and not because of clinical 
or biochemical features. As controls, we used plasma from 10 healthy volun-
teers. Vasopressin samples were taken every time plasma volume was 
determined. Plasma volume determinations did not affect the measurements 
of arginine vasopressin. Blood samples were taken without the use of a tourni-
quet and were immediately frozen at -70°C. Extraction of plasma samples and 
subsequent radioimmunoassay were carried out as described in detail 
elsewhere (28).Briefly, 20 mg ofVycor glass powder was added to the samples 
and after vigorous shaking the samples were centrifuged. Supernatants were 
discarded and the pellets were washed with cold water and 1 N hydrochloric 
acid. Pellets were resuspended in an aqueous acetone solution. After shaking 
and centrifugation, the supernatants were evaporated under a mild nitrogen 
stream. Residues were redissolved in a barbital buffer, pH 8, containing 5 mg 
human serum albumin per millimeter for subsequent measurements of 
arginine vasopressin by radioimmunoassay using a specific antiserum, W1E, 
which showed almost no cross reactivity (0.01 %) with oxytocin. The inter-
assay and intraassay coefficients of variation were 11.9% and 14.8%, 
respectively. Tracer arginine vasopressin was prepared using the iodogen 
method, which is described elsewhere (106). The whole procedure, except the 
iodination, was carried out at 4°C. 
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RESULTS 
Hyponatremia and Changes in Plasma Volume 
Hyponatremia developed in 9 of the 21 patients on an average of 7 days after 
subarachnoid hemorrhage (range 3 to 9 days). In these 9 patients the serum 
sodium levels dropped to a median of 131 mmol/L (range 129 to 134 
mmol/L). The sodium levels declined gradually and then normalized again 
without any therapeutic measure after an average interval of 4.5 days (range 
2 to 9 days). 
The plasma volume decreased between 10 and 20% in 6 of the 9 patients 
with hyponatremia, decreased less than 10% in 2, and increased 4% in 1. Of 
the 12 patients in whom sodium levels remained normal, plasma volume 
decreased more than 10% in 5 and less than 10% in 3. In 4 of these 12 patients 
plasma volume increased from 5 to 28% (Figure 1 ). The proportion of patients 
with a decrease in plasma volume of more than 10% was not significantly 
different in patients with normal sodium values (5 of12 patients) compared 
with patients with hyponatremia (6 of 9 patients) (Fisher's exact test, p 2 = 
0.3). 
Sodium Balance 
The actual fluid and sodium intake and output in patients with hypo-
natremia and patients with normal sodium values are illustrated in Figures 2 
and 3. In 8 of the 9 patients who developed hyponatremia, we found a 
negative sodium balance, which always preceded the developmelft of hypo-
natremia; 4 patients without hyponatremia also had a negative sodium 
balance. There was no difference in sodium intake between patients who had 
normal sodium values and patients who developed hyponatremia. 
Plasma volume decreased more than 10% in 10 of the 12 patients with a 
negative sodium balance, and in only 1 of the 9 patients with a positive 
sodium balance. The difference is statistically significant (Fisher's exact test, 
p < 0.01). 
30 
20 
10 
Change 
in plasma 
volume[%] 
0 
-10 
-20 
-30 
29 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
• 
• 
• 
• 
-• 
• 
• 
Normal sodium Hyponatremia 
levels 
Figure l. Plasma volume changes in 21 patients with a ruptured aneurysm. (open circles= 
normal sodium level; closed circles = hyponatremia). 
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Figure 2. Sodium balance in patients with a plasma volume decrease ofless than I 0% (stars= 
data expressed in mmol, circles= data expressed in liters). 
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Figure 3. Sodium balance in patients with a plasma volume decrease of more than I 0%. (stars= 
data expressed in mmol; circles= data expressed in liters). 
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Hyponatremia and Other Laboratory Findings 
We have summarized in the Table the results on admission and at the time of 
the second plasma volume determination. The thyroxine values ranged from 
75 to 124 nmol/L (median 110). The cortisol values ranged from 215 to 717 
nmol/L (median 496). The creatinine clearance ranged from 79 to 189 
ml!minute (median 124). These values are within normal limits. 
In none of the patients high glucose levels were observed. In 3 of the 21 
patients a temporary glucosuria was observed during the first days of 
observation. 
Table 1. Laboratory findings in patients with normal sodium levels and hyponatremia* 
Normal sodium Hyponatremia 
Laboratory measurement Range Median Range Median 
Hematocrit (%) 35-47 41 35-46 42 
37-49 46 35-47 42 
Blood urea nitrogen 3.6-7. 7 5.8 2.8-8.3 5.7 
( mmol/liter) 2.7-9.7 7.1 2.7-8.4 7.9 
Creatinine (J.Lmol/liter) 58-103 70 49-98 68 
61-99 86 52-124 69 
Plasma osmolality (mOsm) 276-298 289 273-306 287 
266-300 2&0 272-300 275 
Urine osmolality (mOsm) 356-1064 767 501-805 671 
280-805 570 456-927 794 
*Top number= values on admission; bottom number =values at the time of the second plasma 
volume determination. 
Hyponatremia and Body Weight 
Body weight was repeatedly measured in patients who developed hypo-
natremia and decreased in all (range l to 2.2 kg; median 2 kg). The caloric 
intake ranged from 1,67 kilojoules to 7,350 kilojoules (median 4,691 kilo-
joules), so weight loss in this short time span cannot have resulted from caloric 
insufficiency. Body weight loss in patients who developed volume depletion 
and did not develop hyponatremia was within the same range. 
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Hyponatremia and Arginine Vasopressin Levels 
Of the 19 patients in whom arginine vasopressin was measured, 8 developed 
hyponatremia, with levels ranging from 1.1 to 14.3 pg/ml (median 2.3 
pg/ml). The 11 patients without hyponatremia showed similar or even 
higher values. On second measurement (6 days after subarachnoid hem-
orrhage or earlier if hyponatremia developed), the arginine vasopressin levels 
had decreased whether hyponatremia occurred or not (range 0.1 to 2.6 
pg/ml; median 1.6 pg/ml). Levels remained slightly elevated compared with 
control levels (range 0.6 to 2.5 pg/ml; median 0.7 pg/ml) (Figure 4). There 
was no association in the second week between changes in plasma volume and 
levels of arginine vasopressin. 
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Figure 4. Arginine Vasopressin values in 19 patients with a ruptured aneurysm (open circles= 
normal sodium values, closed circles= hyponatremia, SAH =subarachnoid hemorrhage). 
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Clinical Features 
The level of consciousness on admission, measured with the Glasgow coma 
scale (120), was not different in patients with continuously normal sodium 
values and in patients who later developed hyponatremia. 
Ten of the 21 patients deteriorated clinically, 9 from rebleeding and l from 
cerebral infarction, which was confirmed by CT scan. None of the deterio-
rations was related to low serum sodium values. 
DISCUSSION 
This study demonstrates that hyponatremia in patients with an aneurysmal 
subarachnoid hemorrhage is associated with a decrease in plasma volume in 
most patients and with a decrease in body weight in alL The combination of 
hyponatremia and decreased plasma volume was always preceded by a 
negative sodium balance. In addition, the blood urea nitrogen increased in 
patients with hyponatremia. Serum vasopressin levels were increased on 
admission in most patients and decreased during the first week whether or not 
hyponatremia developed. The initial rise of vasopressin levels may be related 
to a sudden increase in intracranial pressure or to the onset pain of 
subarachnoid hemorrhage (9, 75, 82). All these findings are consistent with a 
salt wasting syndrome rather than with inappropriate secretion of antidiuret-
ic hormone. On the other hand, 3 patients with hyponatremia did not show a 
fall in plasma volume (it even increased in one). It is possible that in these 
patients natriuresis was followed by a renal compensation of water excretion. 
A surprising finding is that plasma volume decreased considerably in half 
of the patients, including some without hyponatremia. With one exception, 
all these patients had a negative balance caused by excessive natriuresis. 
Excessive loss of sodium in the urine may be caused by inhibition of tubular 
sodium reabsorption with a concurrent loss of extracellular fluid, resulting in 
a decrease in plasma volume. The factor that causes the inhibition of tubular 
reabsorption in subarachnoid hemorrhage is unknown. This natriuretic 
factor might be released after damage to the hypothalamus (95). Not all the 
patients with a negative sodium balance developed hyponatremia. It is 
possible that the concomitant renal fluid loss increased the serum sodium 
level and thereby prevented the development of hyponatremia. 
Our observations confirm the previous reports of Nelson and associates (88, 
89). In their clinical study, although done without serial measurements, they 
found subnormal plasma volumes in 6 of 8 patients with subarachnoid 
hemorrhage who had hyponatremia and who fulfilled the laboratory criteria 
for the syndrome of inappropriate secretion of antidiuretic hormone (88). 
The observations in their subsequent report, based on experiments in 
monkeys, clearly showed the development of a negative salt balance before 
hyponatremia occurred, but plasma volumes were not significantly de-
creased (89). 
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Maintenance of an adequate intravascular volume is important in the 
management of patients with aneurysmal subarachnoid hemorrhage (53). 
Patients with subarachnoid hemorrhage are threatened by vasospasm, which 
may lead to cerebral ischemia. Cerebral blood flow may be further impaired 
in patients with an increased blood viscosity caused by volume depletion. 
The importance of an adequate intravascular volume has been corroborated 
by reports describing improvements in signs attributed to cerebral ischemia 
when volume expansion was given (63, 98, 116). The effectiveness of volume 
expansion in increasing cerebral perfusion may be explained by an 
improvement in blood viscosity or by a rise in cardiac output. 
Patients with hyponatremia are especially at risk of developing cerebral 
ischemia (Chapter II). This study confirms that these patients have volume 
depletion and therefore ought to be treated with volume expansion. In 
addition, we demonstrated that a decrease in plasma volume also occurs in 
patients with normal sodium levels. Therefore, monitoring salt balance 
becomes of great importance in patients with subarachnoid hemorrhage. 
When volume depletion coincides with a negative sodium balance, the 
administration of hypertonic sodium or volume replacement seems justified 
(63, 98, 116). However, it remains to be shown that such measures can 
effectively prevent cerebral ischemia. 
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Chapter IV 
THE EFFECT OF ANTIHYPERTENSIVE 
TREATMENT 
INTRODUCTION 
Immediately after aneurysmal subarachnoid hemorrhage (SAH), a quarter 
to half of the patients without a previous history of hypertension have an 
elevated blood pressure (8, 43). The rationale for antihypertensive treatment 
in these patients is to reduce the chance of rebleeding by decreasing the 
pressure against the weakened wall of the aneurysm (43, 125). However, 
reduction of blood pressure might also decrease cerebral perfusion pressure in 
patients with an impaired autoregulation and in this way enhance the risk of 
cerebral ischemia (40, 53). This has been supported by the observation that 
neurological deterioration and a fall in cerebral blood flow occurred when 
dopamine treatment was withdrawn after aneurysm surgery (78). Converse-
ly, ischemic deficits can sometimes be reversed by induced hypertension (17, 
68, 83). 
In this study we reviewed a prospectively collected series of patients to 
investigate the relation between the level of the blood pressure or the 
institution of antihypertensive treatment on the one hand and the develop-
ment of reble'eding or ischemia on the other. 
PATIENTS AND METHODS 
Patients 
We studied 134 consecutive patients with signs and symptoms of subarach-
noid hemorrhage and with CT-scan evidence of extravasated blood in the 
basal cisterns, suggesting a ruptured aneu~ysm (130). Patients with normal 
angiography or another cause of SAH were excluded (133). 
All patients had been entered into a double-blind, placebo-controlled trial 
on the effectiveness of tranexamic acid (136). Computerized tomography 
scanning was carried out on admission and was repeated every week and 
within six hours of any clinical deterioration. 
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Assessment of outcome and of events 
Outcome was assessed at three months according to the five-point Glasgow 
outcome scale (60). For the purpose of analysis this scale was.collapsed into 
three groups, viz. dead,· persistent vegetative state/severe disability (i.e. 
dependent), and moderate disability/good recovery (i.e. independent). 
Cerebral infarction was diagnosed if a patient had gradually deteriorated 
and developed a focal neurological deficit, with or without evidence of 
infarction on repeat CT scans, or if a gradual deterioration of consciousness 
had occurred (at least one point on the motor score of the Glasgow Coma 
Scale) with CT confirmation ()f ischemic changes (136). 
Rebleeding was diagnosed if a sudden deterioration was associated with in-
creased hemorrhage on a CT scan or at autopsy, on comparison with the 
previous CT scan, or when sudden deterioration and death occurred without 
the possibility ofproofby CT scanning and when autopsy was refused (136). 
All patients were under continuous observation in an intensive care unit. 
Blood pressures were measured and recorded every three hours by the usual 
manometric method, from the day of admission until the 14th day or until 
operation or death. The average of these daily measurements was calculated 
for both systolic and diastolic values from the values at 6, 12, 18 and 24 hours. 
In patients who had been on antihypertensive medication before the hemor-
rhage, this treatment was discontinued. Antihypertensive treatment was 
started if a single recording showed a diastolic blood pressure ofl10 mm Hg 
or more. These patients were treated with at least 150 micrograms clonidine 
intramuscularly. The aim was to bring back the diastolic blood pressure to 
levels under ll 0 mmHg. When it was not possible to lower the blood pressure 
with doses of clonidine up to 900 micrograms daily, ,8-blocking agents or 
diuretics were added. 
Some factors that were taken into account because they are known to be 
associated with an increased incidence of cerebral infarction were defined as 
follows: 
Hyponatremia was defined as a sodium level lower than 135 mmol/L on at 
least two consecutive days, in the absence ofhyperlipidemia and paraprotei-
nemia. Serum sodium levels were measured at least three times a week. 
The amount of cisternal and intraventricular blood was graded as described 
before (56, 133). 
As a linear measurement of ventricular size, we used the bicaudate index, 
that is the width of the frontal horns at the levels of the caudate nuclei divided 
by the corresponding diameter of the brain. The width of the third ve)J.tricle 
was measured on the slice where the third ventricle had the maximal trans-
verse diameter. The bicau<:late index and the width of the third ventricle were 
converted into a relative size by dividing the absolute values by the upper 
limit for age, as described elsewhere (134) and in detail in Chapter V. 
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Statistical analysis 
Distributions in 2 X 2 tables were analyzed with the Chi-square test. 
Combined 2 X 2 tables were analyzed with the Mantel-Haenzel test. The 
significance of the different factors that were associated with cerebral 
ischemia were assessed by means of logistic regression. 
RESULTS 
Eighty of the 134 patients (60%) were given antihypertensive medication soon 
after admission. To 53 of these 80 patients, only clonidine was given, in four to 
six intramuscular gifts per day. In the remaining 27 patients (34%) clonidine 
alone did not sufficiently reduce the blood pressure, for which reason it was 
combined with other antihypertensive drugs: ,8-blocking agents in 10, 
diuretics in nine, both ,8-blocking agents and diuretics in three, and ,8-
blocking agents as well as other antihypertensives in five. 
The Figure shows the comparison of average systolic and diastolic blood 
pressures among patients with and without antihypertensive treatment. 
Diastolic blood pressures in treated patients were kept below 110 mm Hg, 
but still remained around 100 mm Hg. The mean systolic blood pressure in 
the treated patients was about 160 mm Hg. On average, both diastolic and 
systolic pressures were still higher than in patients without antihypertensive 
treatment. 
Antihypertensive treatment and outcome 
Review three. months after the hemorrhage showed that there was no signifi-
cant difference in outcome between the patients who were given antihyper-
tensive treatment and patients with normal blood pressures (Table l ). 
Death occurred in 41 of 80 patients (51%) treated with antihypertensive 
drugs, and in 27 of 54 patients (50%) not treated with antihypertensive drugs. 
Antihypertensive treatment and rebleeding 
Rebleeding occurred in 30 (22%) of the 134 patients. Although the 80 patients 
treated with antihypertensive drugs had on average a higher blood pressure 
than patients without antihypertensive treatment(Figure), only 12 (15%) had 
a rebleed, whereas rebleeding occurred in 18 (33%) of the 54 patients without 
antihypertensive treatment ( X2 = 6.23, 1 df, p = 0.012). 
The only other factor related to rebleeding was treatment with tranexamic 
acid, also in an inverse direction. Of the patients on antihypertensive 
treatment, slightly less than half were treated with tranexamic acid (38/80), 
versus precisely half of the remaining patients (27/54). Factors such as a 
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Table I. Outcome at three months in 134 patients with SAH. (No. of patients (%)). 
Outcome* Antihypertensive drugs No antihypertensive drugs 
Dead 41 (51) 27 (50) 
Dependent 10 (13) 5 ( 9) 
Independent 29 (36) 22 (41) 
Total 80 (!00) 54 (100) 
*In our study the Glasgow outcome scale was collapsed into three groups, viz. dead, dependent 
(persistent vegetative state or severe disability) and independent (moderate disability or 
good recovery). 
history of cardiovascular disease (TIA's, angina, myocardial infarction, 
brain infarcts), history of hypertension, loss of consciousness at ictus, the 
amount of blood on CT, level of consciousness on admission, age and sex, 
were all not significantly related with rebleeding. 
Antihypertensive treatment and cerebral infarction 
Cerebral infarction occurred in 46 (34%) of all patients in the series. Of those 
treated with antihypertensive drugs, 32 (40%) had a cerebral infarct, 
compared with only 14 (26%) of the patients without antihypertensive treat-
ment ( x2 = 6.07, p = 0.014). 
The factors associated with cerebral infarction in this group of patients are 
shown together in Table 2. Hyponatremia was the most powerful risk factor, 
and the other risk factors were also assessed after correction for hyponatremia 
(Table 2). Cerebral infarction occurred 2 to 14 days (mean 6 days) after the 
Table 2. Factors associated with cerebral infarction. 
After adjustment for 
hyponatremia 
xz p xz p 
Variable (1 d.f.) value (1 d.f.) value 
Loss of consciousness 5.35 0.021 6.12 0.013 
History of cardiovascular disease 4.20 0.040 6.40 0.011 
Enlarged lateral ventricles 1.76 0.185 0.35 0.554 
Enlarged third ventricle 3.70 0.054 0.68 0.411 
Cisternal blood 8.89 0.003 5.46 0.019 
Intraventricular blood 7.66 0.006 4.25 0.039 
Tranexamic acid treatment 4.85 0.028 3.12 0.077 
Antihypertensive treatment 6.07 0.014 3.11 0.078 
Hyponatremia 20.85 <0.001 
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development of hyponatremia. After adjustment for hyponatremia the 
incidence of infarction in patients treated with antihypertensive drugs is still 
higher than in patients without this treatment, but the difference is no longer 
statistically significant (p = 0.078). The confounding association between 
antihypertensive treatment and hyponatremia was not statistically signifi-
cant in its own right (p = 0.059) and there was no relation between diuretic 
treatment and hyponatremia ( x2 = 0.36, 1 df, p = 0.54). 
In the 104 patients who had no previous history of hypertension, the asso-
ciation between antihypertensive treatment and cerebral infarction was also 
statistically significant (p < O.OZ, Table 3). In the 30 patients known to be 
hypertensive, this was not the case, but only three patients did not receive 
antihypertensive treatment. On the whole, the incidence of cerebral 
infarction was higher in patients with previous hypertension than in those 
without such history, although this difference did not reach statistical 
significance (p = 0. 11). 
Table 3. Incidence of cerebral infarcts related to history of hypertension and antihypertensive 
drugs. 
Antihypertensive No antihypertensive Total 
drugs drugs cases 
History of hypertension 
total cases 27 3 30 
no. infarcts 12 2 14 
%infarcts 44 67 47 
No history of hypertension 
total cases 53 51 104 
no. infarcts 22 10 32 
% infarcts 42 20 31 
Totals 
total cases 80 54 134 
no. infarcts 34 12 46 
%infarcts 43 22 34 
Blood pressure levels just before rebleeding or infarctiort 
Because the blood pressures before rebleeding or infarction might show a 
temporary change, we alse looked at the blood pressure levels just before 
these events. We compared the average blood pressures during the last 24 
hours before rebleeding with the average values during the last 24 hours 
before the first signs of cerebral ischemia developed. 
The pre-event blood pressure levels corresponded well with the levels in the 
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first week after admission, in that patients with infarcts had higher blood 
pressures - and more often antihypertensive treatment - than patients with 
rebleeds" (Table 4). In patients with rebleeds, 7 (23%) had an average systolic 
blood pressure higher than 160 compared with 21 patients ( 46%) with infarcts 
( x2 = 3.88, p = 0.048). Similarly, four patients (13%) who rebled had an 
average diastolic pressure higher than 100, while 17 (37%) with infarcts had 
these values ( X2 = 5.06, p = 0.024). 
Table 4. Average systolic and diastolic blood pressure values 24 hours before rebleeding 
and cerebral infarction. (No. of patients %) ). 
Average systolic 24 hours before 24 hours before 
blood pressure rebleeding cerebral infarction 
120-140 mm Hg 8 (27) 5 (II) 
141-160 mm Hg IS (50) 20 (43) 
161-180 mm Hg 7 (23) II (24) 
181-200 mm Hg 0 10 (22) 
Total 30 46 
Average diastolic 24 hours before 24 hours before 
blood pressure rebleeding cerebral infarction 
'i( 80 mm Hg 5 (17) 3 ( 6) 
81-100 mm Hg 21 (70) 26 (57) 
101-120 mm Hg 4 (13) 16 (35) 
121-140 mm Hg 0 I ( 2) 
Total 30 46 
In addition, fluctuations in systolic and diastolic pressures (the difference 
between highest and lowest values) during the last 24 hours before a rebleed 
were compared with fluctuations during the 24 hours before the signs of 
cerebral ischemia developed (Table 5). 
Fluctuations of more than 40 mm Bg of systolic values were more often found 
in patients with infarcts, but not statistically significant (0.1 > p > 0.05). 
Table 5. Fluctuation of blood pressure (difference<between highest and lowest value) during 
24 hours before rebleeding or infarction. SBP =systolic blood pressure; DBP =diastolic blood 
pressure. (No. of patients (%)). 
Fluctuation 24 hours before 24 hours before 
of blood rebleeding cerebral infarction 
pressure in 
lllDl Hg SBP DBP SBP DBP 
0-20 16 (53) 17 (57) 16 (35) 19 (41) 
21-40 8 (27) 12 (40) 11 (24) 21 (46) 
41-60 4 (13) 1 (3) 10 (22) 4 ( 9) 
>60 2 ( 7) 0 9 (19) 2 ( 4) 
Total 30 30 46 46 
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No dependence between cerebral rebleeding and infarction 
To investigate if antihypertensive treatment decreased the incidence of 
rebleeds by increasing the number of deaths from infarction, which would 
leave fewer patients at risk ofrebleeding, we compared the distribution of the 
times to the first event (rebleeding or infarction). 
The times to rebleeding or infarction were similarly distributed (Wilcoxon 
test t = 86.5, p > 0.05). In addition, the reduced incidence ofrebleedingwith 
antihypertensive drugs was also evident in patients without infarction; 8 of 45 
or 18% rebled with antihypertensive treatment, and 14 of 43 or 32% without 
these drugs. 
DISCUSSION 
This study demonstrates that antihypertensive treatment did not improve 
outcome at three months in patients with aneurysmal subarachnoid hemor-
rhage. The patients were not randomized to antihypertensive treatment, 
but treatment was started when diastolic blood pressures were higher than 
110 mm Hg and our intention was to reduce the diastolic blood pressure 
below 110. Despite this, the average blood pressures in patients treated with 
antihypertensive drugs remained higher than in patients without this treat-
ment. Although the outcome was similar, there was a significant difference in 
both rebleeding and infarction rates in patients with antihypertensive treat-
ment: fewer rebleeds and more infarcts occurred, notwithstanding the higher 
blood pressures. 
The higher incidence ofrebleeding in the untreated group could neither be 
explained by temporarily high blood pressures during the last 24 hours before 
the rebleed, nor by marked systolic or diastolic fluctuations. The only other 
factor that showed a significant negative relation with rebleeding, treatment 
with tranexamic acid, proved to be independent. 
The increased incidence of infarction (often with fatal outcome) after 
antihypertensive treatment might theoretically account for the reduction in 
the rebleeding rate, because fewer patients might be left at risk for rebleeding. 
However, the times to the onset of rebleeding and infarction were similar, 
and antihypertensive treatment reduced rebleeding also in patients without 
infarction. 
The increased infarction rate in patients treated with antihypertensive 
drugs cannot simply be attributed to low blood pressures, because the 
average blood pressures in these patients were still higher than in patients 
without antihypertensive treatment. Pre-existing hypertension had to be 
discounted as an underlying factor, because antihypertensive treatment also 
increased the infarction rate in patients without such a history. When we 
related the association between antihypertensive treatment and cerebral 
infarction with other factors associated with cerebral infarcts, hyponatremia 
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proved to be the most significant of all. After adjustment for hyponatremia 
the rate of infarcts in patients treated with antihypertensive drugs is still 
higher but the significant association disappeared. The association between 
antihypertensive treatment and hyponatremia was weak, however. It could 
not be attributed to diuretic treatment. 
Are the results of this study in keeping with those of others? Richardson et 
al. found a relationship between hypertension and rebleeding in patients 
with anterior communicating aneurysms, but not with posterior commu-
nicating aneurysms (101, 102). Nibbelink et al. found an increased rebleed 
rate in patients treated with drug-induced hypotension (90). Therefore, the 
common notion that high blood pressures predispose to rebleeding has little 
support from previous series, although rebleedingwas poorly defined in these 
studies. The diagnosis was based mainly on clinical features, and it has been 
demonstrated that this results in an overestimation of the rebleeding rate 
(137). 
What might be the explanation for the paradoxa! finding that antihyper-
tensive treatment, although resulting in blood pressures that are still higher 
than in untreated patients, yet increases infarction and decreases rebleeding? 
Hypertension itself or antihypertensive treatment might inhibit fibrinoly-
sis. This would explain the decreased rate of rebleeding and perhaps also the 
increased rate of infarction, since inhibition of fibrinolysis - at least by 
tranexamic acid - is accompanied by an increased incidence of infarcts. 
However, such an effect of high blood pressure or of antihypertensive treat-
ment (in particular clonidine, {3- blocking agents and diuretics) has never 
been reported (79). 
Many factors contribute to the pathogenesis of cerebral ischemia (56). 
Vasospasm, often identified with cerebral ischemia, could not be assessed in 
our study, because angiography was not repeated or even performed in all 
patients. Besides that, hyponatremia proved to be one of the most important 
determinants, probably by the concomitant decrease in plasma volume 
(Chapter III). 
Hypertension might perhaps be considered a response to vasospasm, in 
order to maintain cerebral perfusion pressure, which effect can be negated if 
antihypertensive drugs are given. Nevertheless, the possible relationship 
between antihypertensive treatment and hyponatremia illustrates that the 
order and the interrelationship of these three factors remain obscure. 
The results of this study have practical implications. Until we have further 
knowledge of the incidence of rebleeding and cerebral infarction in patients 
with untreated hypertension, there seems no need for antihypertensive treat-
ment in aneurysmal subarachnoid hemorrhage, since reduction of rebleeding 
is achieved only at the expense of an increased incidence of infarction, with 
similar outcomes as the net result. 
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Chapter V 
ENLARGEMENT OF THE THIRD VENTRICLE 
AND HYPONATREMIA 
INTRODUCTION 
Hyponatremia following aneurysmal subarachnoid hemorrhage (SAH) is 
not an infrequent finding and is associated with an increased risk of cerebral 
infarction (Chapter II). 
Hyponatremia was previously attributed to an inappropriate secretion of 
antidiuretic hormone (27, 61, 70, 129, 148), but recently it was demonstrated 
that hyponatremia is a result of salt wasting (88, Chapter III). What factors 
mediate natriuresis after SAH remains to be established. 
In a previous study, a relationship was found in patients with SAH 
between the development of hyponatremia and the presence of hydro-
cephalus on admission (134). A possible explanation was that enlargement of 
the third ventricle might interfere with hypothalamic function. In that study 
(134), however, the width of the third ventricle was not measured, as the 
diagnosis of acute hydrocephalus was based on the width of the lateral 
ventricles. Therefore, the relationship between hyponatremia and the size of 
the third ventricle was separately investigated. 
PATIENTS AND METHODS 
A review was done of the CT scans ofl34 consecutive patients with signs and 
symptoms of a subarachnoid hemorrhage ahd with computed tomographic 
evidence of extravasated blood in the basal cisterns, suggesting a ruptured 
aneurysm (130). Patients with causes other than a ruptured aneurysm or 
patients with a negative angiogram were excluded (133). CT scanning was 
performed on admission, always within 72 hours of the bleeding, and was 
repeated weekly and after any clinical deterioration. An aneurysm was 
confirmed by angiography or postmortem examination in 99 of the 134 
patients. In 35 patients angiography was not performed because of age over 
65, or poor clinical condition from the initial bleed or from secondary 
deterioration from any cause. In these patients the diagnosis was based on CT 
evidence only, particularly signs of blood in the basal cisterns (130) and 
absence of lesions other than an aneurysm (133). This consecutive series of 
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patients was part of a randomized, double-blind, placebo-controlled trial on 
the effectiveness oftranexamic acid (136). One patient died within 24 hours 
of massive intraventricular hemorrhage and was not included in the analysis. 
The remaining 133 patients were studied for a 4-week period after the 
presenting hemorrhage or until death or operation within this time. During 
this period all patients were under continuous observation in an intensive 
care unit. 52 patients underwent clipping of the aneurysm; most operations 
were carried out on the twelfth day after the presenting hemorrhage. 
The width of the third ventricle on the initial CT scan was measured with a 
transparent ruler from X-ray films, and multiplied by the appropriate 
magnification factor - there were two CT machines - to obtain the real size. 
The slice where the third ventricle had the maximal transverse diameter was 
chosen. The normal values of the third ventricle were used as described by 
Meese (77). The upper limit of normal (90th percentile) was defined as: 5 mm 
at age 40 or under, 6 mm at age 50, 7 mm at age 60 and 9 mm at age 80. The 
width of the third ventricle was converted into a relative size by dividing the 
width of the third ventricle by the upper limit for age. 
The bicaudate index was defined as the width of the frontal horns at the 
level of the caudate nuclei, divided by the corresponding diameter of the 
brain. The bicaudate index was converted into a relative size by dividing the 
bicaudate index by the upper limit for age for each half decade (95th percen-
tile) as previously described (133). 
At the time of measurement, the investigators had no knowledge of the 
clinical condition of the patients and, in particular, they were not aware 
which patients had developed hyponatremia. 
The amount of cisternal blood on the initl.al CT scan was separately graded 
for ten cisterns and fissures. Patients were then distinguished into those with 
no cisternal blood or a small amount in only one cistern or fissure and those 
with frank cisternal hemorrhage. This dichotomy appeared to be related to 
the incidence of infarcts, according to our own data (56) and those of others 
(65). 
Similarly, the amount of intraventricular blood on the initial CT seal) was 
graded separately for each ventricle, on a scale ofO to 3. A total score of2 
usually represented sedimentation of red blood cells in the dependent parts of 
the ventricular system, and only higher scores were regarded as frank intra-
ventricular hemorrhage. 
Hyponatremia was defined as a sodium level lower than 135 mmol/L on at 
least two consecutive days, in the absence of hyperlipemia or hyper-
proteinemia. Serum sodium levels were measured on admission and at least 
three times a week. 
CT scanning was repeated weekly and after each clinical deterioration. 
Cerebral infarction was diagnosed if (1) there were new focal signs or a 
decrease in the level of consciousness, usually of gradual onset; and (2) CT 
showed a hypodense lesion compatible with the clinical signs, or there were 
no lesions other than infarction that could explain the clinical signs. 
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RESULTS 
In this series of 133 patients, the admission CT scan showed enlargement of 
the lateral ventricles and also of the third ventricle in 26 patients (20%), of the 
third ventricle only (Figure I) in 15 patients (II%), and of the lateral 
ventricles only (Figure 2) in 3 patients (2%). Hyponatremia developed in 44 of 
the 133 patients (33%), always between day 2 and day 10 (median day 4) 
after the hemorrhage. It was mild (130 to 134 mmol/L) in 18, moderate (125 
to 129 mmol/L) in 20 and severe (120 to 124 mmol/L) in 6 patients. 
Figure l. Initial scan showing normal relative size of the lateral ventricles [bicaudate index 
(0.19) divided by the upper limit for age 57 (0.19) equals 1.00] and enlargement of the third 
ventricle [third ventricle size (8 mm) divided by the upper limit for age 57 (7 mm) equals 1.4]. 
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Figure 2. Initial CT scan showing increased relative size of the lateral ventricles [bicaudate 
index (0.19) divided by the upper limit for age 41 (0.17) equals 1.12] and normal size of the 
third ventricle [third ventricle size (6 mm) divided by the upperlimit for age 41 (6 mm) equals 
1.0]. 
Figure 3 illustrates the relative size of the third ventricle in patients with 
and without hyponatremia. It is clear that hyponatremia more often 
developed in patients with an enlarged third ventricle on admission ( x2 -
test, p < 0.05). However, the degree of hyponatremia (not shown) did not 
linearly correlate with the degree of ventricular enlargement. 
number of 
patients 
15 
10 -
5 
-
r-
I I 
1-
53 
-
-
- -
-
-
I 1- 011 n n 
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 
Relative third ventricle size 
Figure 3. Diagram showing the distribution of relative third ventricle size (absolute width 
divided by upper limit for age) in patients with normal sodium values and in patients with 
hyponatremia (black bars). 
The incidence of hyponatremia in the three subgroups of patients with 
hydrocephalus was compared with that in patients with normal ventricles 
(Table 1). Hyponatremia occurred significantly more often in patients with 
enlargement of the lateral ventricles as well as of the third ventricle, and also 
in patients with isolated enlargement of the third ventricle. An increased size 
of the lateral ventricles but not of the third ventricle was found in only three 
patients, which makes it impossible to draw conclusions about an association 
with hyponatremia in this category. 
The relationship between hyponatremia and enlargement of the third 
ventricle was separately analyzed for the patients with marked hyponatremia 
(sodium levels 120-130 mmol/L). Fourteen of the 26 patients with marked 
hyponatremia had an enlarged third ventricle as opposed to 27 ofthe 107 
patients with normal sodium levels or mild hyponatremia (130-135 mmol/L) 
(X2 test, p < 0.01). 
Serial CT scans were done in 113 patients, including all 44 patients with 
hyponatremia. At the time of hyponatremia, the CT scan showed an 
enlarged third ventricle in 25 of the 44 patien.ts, compared with 26 of the 69 
patients who maintained normal sodium ( x2 test, p < 0.05 ). 
Table L 
Ventricular size on the 
initial CT scan 
Enlargement of third ventricle 
with enlarged lateral ventricles 
with normal lateral ventricles 
Normal third ventricle 
with enlarged lateral ventricles 
with normal lateral ventricles 
Total 
54 
Hyponatremia 
12* 
8** 
2*** 
22 
44 
*p2 = 0.05 
**p2 = 0.03 
***N.S. 
Fisher's exact probability test 
Normal 
serum sodium Total 
14 26 
7 15 
l 3 
67 89 
89 133 
The relationship between enlargement of the third ventricle and hypona-
tremia remained after adjustment for the amount of cisternal blood (Mantel-
Haenzel test, p = 0.02 (see Table 2)). In keeping with this, an earlier study 
failed to show an association between the extent of cisternal hemorrhage and 
enlargement of the lateral ventricles (134). 
Table 2. 
Amount of cisternal blood Total 
Frank Small or absent cases 
Enlarged third ventricle 
Total cases 35 6 41 
no. hyponatremia 18 2 20 
% hyponatremia 51 33 49 
Normal third ventricle 
Total cases 76 16 92 
no. hyponatremia 23 l 24 
% hyponatremia 30 6 26 
Totals 
Total cases Ill 22 133 
no. hyponatremia 41 3 44 
% hyponatremia 37 14 33 
Frank intraventricular hemorrhage was found in 18 of the 44 patients with 
hyponatremia versus 19 of the 89 patients with normal serum sodium levels 
(Fisher's exact test, p = 0.02). 
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After adjustment for intraventricular hemorrhage, the association between 
initial enlargement of the third ventricle and hyponatremia no longer 
reached statistical significance (0.05 < p < 0.10). This is explained by a 
separate but statistically weaker relationship between intraventricular 
hemorrhage and hyponatremia, after adjustment for initial enlargement of 
the third ventricle (0.10 < p < 0.20; Table 3). 
Table 3. 
Intraventricular blood Total 
Frank Small or absent cases 
Enlarged third ventricle 
Total cases 21 20 41 
no. hyponatremia 12 8 20 
% hyponatremia 57 40 49 
Normal third ventricle 
Total cases 17 75 92 
no. hyponatremia 6 18 24 
% hyponatremia 35 24 26 
Totals 
Total cases 38 95 133 
no. hyponatremia 18 26 44 
% hyponatremia 47 27 33 
Intraventricular hemorrhage was very strongly related to initial enlargement 
of the third ventricle (21141 versus 17/92, p < 0.001; Table 3). 
Cerebral infarcts occurred more often in patients with initially enlarged third 
ventricles (18/41 = 44%) than in patients who had a normal third ventricle 
(28/92 = 30%). This difference did not reach statistical significance. Fatal 
infarcts were more frequent in patients with initial enlargement of the third 
ventricle (9/41 = 23%), versus 9/92 (10%) inpatientswhohadanormal third 
ventricle (not statistically significant, 0.05 < p < 0.01). 
An aneurysm was demonstrated by angiography or at postmortem 
examination in 31 patients with hyponatremia. Of these, 13 had an aneurysm 
of the anterior communicating artery (42%), 11 of the carotid artery (35%), 3 
of the middle cerebral artery (9%) and 4 of the posterior circulation (13%). For 
the 68 patients with normal sodium levels and a proven aneurysm, the 
distribution was similar: 26 (38%), 22 (32%), 13 (9%) and 7 (10%), respectively. 
Nine patients with an enlarged third ventricle underwent ventricular 
drainage, six of whom had developed hyponatremia. In four of these six 
patients the size of the third ventricle did not change after shunting, and 
hyponatremia persisted. In the two other patients, both the size of the third 
ventricle and the sodium level returned to normal after ventricular drainage. 
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DISCUSSION 
The risk of developing hyponatremia after SAH was found to be significantly 
increased in patients with enlargement of the lateral ventricles as well as of 
the third ventricle on the admission CT scan, and also in patients with 
enlargement of only the third ventricle. This suggests that the size of the third 
ventricle is the crucial factor in the relationship that was previously found 
between acute hydrocephalus and hyponatremia (134). Furthermore, the 
relationship between an initially enlarged third ventricle and subsequent 
hyponatremia remained at more marked levels of hyponatremia and 
continued to exist during the actual period of hyponatremia. 
The pathogenesis of hyponatremia after SAH is not known. It has been 
suggested that the hypothalamus may be damaged by rupture of an 
aneurysm of the anterior circulation (22, 118) and that this damage may 
result in disturbances of the electrolyte balance (93). However, a difference in 
the distribution of aneurysms in patients with or without hyponatremia could 
not be demonstrated in our series. 
Another possibility is that hyponatremia is caused by hypothalamic dys-
function secondary to spasm of vessels which supply the hypothalamus. Since 
vasospasm is often multifocal, it might - in this view - account for both 
hyponatremia and cerebral infarction. If this hypothesis were true, an 
association between the amount of cisternal blood and hyponatremia should 
be found, as cerebral ischemia is associated with the amount of cisternal 
blood (56, 65). However, after adjustment for the amount of cisternal blood, 
the relationship between enlargement of the third ventricle and hyponatre-
mia remained unaltered. In contrast, the significant relationship between 
enlargement of the third ventricle and hyponatremia was weakened after 
adjustment for the amount of intraventricular blood. The direct contribution 
of intraventricular hemorrhage towards the development ofhyponatremia is, 
however, small, and the main effect of intraventricular blood is that it causes 
enlargement of the third ventricle which then results in hyponatremia. 
Now that it has been shown that enlargement of the third ventricle is an 
important factor in the development of hyponatremia, with some contribu-
tion of intraventricular blood, a better explanation might be that mechanical 
pressure on the hypothalamus from within the third ventricle is responsible 
for hyponatremia. This is further supported by the observation that 
hyponatremia persisted when ventricular drainage did not result in a 
decreased size of the third ventricle, whereas·hyponatremia disappeared 
if the third ventricle did shrink. This is in agreement with an observation of 
Wise (147). In his report two patients developed hyponatremia after 
obstruction of a previously placed ventriculo-atrial shunt, and the sodium 
levels again became normal following revision of the shunt. 
Dysfunction of the hypothalamus might cause hyponatremia in different 
ways. It was originally thought that hypothalamic lesions might functionally 
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isolate the osmoreceptors leading to an inappropriate and excessive ADH 
release (27). However, the recent findings of volume depletion and salt 
wasting in patients with hyponatremia after SAH do not support this 
hypothesis (88, Chapter III). An alternative explanation for salt wasting after 
SAH is that dysfunction of the hypothalamus has an effect on the heart 
resulting in the release of the atrial natriuretic factor (ANF) which in turn 
causes salt wasting (93). Such a course of events might be related to changes in 
the heart that have been described after SAH (29). This hypothesis might be 
tested with the recently developed assays that detect the atrial natriuretic 
factor in plasma. Another explanation might be that pressure on the 
hypothalami.rs by the third ventricle causes the release of natriuretic pep tides 
that are present in the anteroventral region of the third ventricle (93). 
Finally, although enlargement of the third ventricle is important in the 
development of hyponatremia, it is neither a necessary nor a sufficient factor, 
as half of the patients with hyponatremia had a normal ventricular system, 
and half of the patients with an expanded third ventricle had constant levels 
of sodium. It might be that natriuresis has causes other than hydrocephalus, 
and that it does not always result in hyponatremia. 
Patients with SAH who develop hyponatremia are at a greater risk of 
cerebral infarction. This was demonstrated earlier in the same group of 
patients, although fluid restriction was a confounding factor (Chapter II). 
Since hyponatremia is caused by natriuresis and is accompanied by hypo-
volemia (Chapter III), fluid restriction might have aggravated a hypo-
volemic state resulting in ischemia. That the volume status plays a role in the 
development of ischemia is further supported by reports that an increase in 
plasma volume reverses cerebral ischemia (63). 
The limits of our sample size and the contribution of other factors in the 
pathogenesis of cerebral ischemia may explain why a direct relationship 
between enlargement of the third ventricle and subsequent infarction could 
not be demonstrated. Nevertheless, the presence of a large third ventricle on 
the initial CT scan indicates that such patients are at a greater risk of 
developing hyponatremia and therefore need a careful control of the fluid 
and sodium balance to prevent cerebral ischemia. 
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Chapter VI 
DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCE 
INTRODUCTION 
Hyponatremia after SAH has been attributed to the syndrome of in-
appropriate secretion of antidiuretic hormone (21 ). It has been demonstrated 
that hyponatremia in SAH is preceded by a negative sodium balance and 
that it is associated with a decrease in plasma volume (7, Chapter III). The 
vasopressin levels were initially high but had decreased when hyponatremia 
developed (Chapter III). Therefore, the older explanation for hyponatremia 
after SAH, cerebral salt wasting (21, 95, 144), is more plausible than the in-
appropriate antidiuretic hormone syndrome. What factor causes natriuresis 
after SAH is not known. 
We investigated if an endogenous digoxin-like substance, which is known to 
enhance sodium excretion by inhibiting sodium transport in the kidney (24), 
was detectable in the plasma of patients with SAH during the first days after 
the hemorrhage. 
PATIENTS AND METHODS 
Patients 
We studied twenty-five consecutive patients with signs and symptoms ofSAH 
who showed computed tomographic evidence of blood in the basal cisterns 
indicating a ruptured aneurysm. 
Reasons for exclusion from the series were an interval of more than 48 hours 
since the presenting hemorrhage, death within six days, endocrine disturb-
ances, heart failure, renal failure, neoplasm and treatment with .diuretics, 
steroids or digoxin. In 22 of the 25 patients an aneurysm was demonstrated by 
angiography or postmortem examination. In the other three patients, 
angiography and surgical treatment were not considered because of age (over 
70) or impaired level of consciousness. However, rupture of an aneurysm in 
these patients was considered highly probable because of the presence of 
blood in the interhemispheric, supr:asellar or sylvian cisterns without 
evidence of another cause of SAH (130, 133). All patients were under 
continuous observation in an intensive care unit and were studied for ten days 
after admission. In most patients clipping of the aneurysm was carried out on 
the twelfth day. 
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Fluid and sodium balance, and blood pressure 
We obtained daily measurements of electrolytes, blood urea nitrogen, 
creatinine, serum osmolality and hematocrit. All patients had a minimal 
fluid intake of 1 ,500 ml per 24 hours. 
The sodium intake was calculated from the sodium content of the food, 
which was specially prepared, and from the sodium content of the fluids 
intravenously administered. Sodium excretion was measured in 24-hour 
urine samples. Salt balance was considered negative when sodium excretion 
in the urine was larger than the daily sodium intake. Loss of sodium from the 
skin or in the feces was not included in the calculation of the sodium balance. 
The mean blood pressure was calculated from four blood pressures taken at 6-
hour intervals at 6, 12, 18 and 24 hours. Hypertension was defined as a mean 
blood pressure (diastolic value + 1/3 of the pulse pressure) of 120 or more on 
at least one day. 
R.I. A. for digoxin-immuno-activity 
The plasma level of the digoxin -like factor was determined in blood, drawn in 
heparinized plastic tubes, which was centrifuged and stored at -70°C. The 
magnitude of the digoxin-like factor was determined by competitive displace-
ment of 1251 digoxin from antidigoxin antibodies relative to digoxin 
standards. The determination of digoxin-like immunoreactive substances 
(DLIS) was done by means of a radioimmunoassay (RIANEN TM Digoxin, 
New England Nuclear, cat. no. NEA-082). 
The procedure prescribed by the manufacturer in the instruction manual 
for this assay was followed with a few modifications. In order to increase the 
sensitivity we examined different combinations of volumes for standards/ 
samples, tracer and antiserum complex. Without performing an extensive 
search for the lowest possible detection limit we found the following 
modifications in the original instruction manual suitable for our study: 
The volume of standards and samples was increased from 100 to 200 J.Ll. The 
volume of tracer was reduced from 500 to 200 ,ul. 
Standards 0.00- 0.05- 0.10- 0.20- 0.30- 0.50- 1.00- 2.00 and 4.00 ng 
digoxin/ml were prepared by dilution of a 8.00 ng/ml standard with "0" 
standard. This resulted in a typical standard curve with values for the 
normalized percent bound or %B/Bo of: 100.0- 92.2- 86.2- 73.5- 65.8-
51.1 - 33.7 - 19.3 and 9.0%, respectively. The lower limit of sensitivity was 
0.05 ng/ml. 
For the determination ofDLIS, samples were diluted 1:3 with deionized 
water in glass tubes and placed in a boiling water bath for 5 minutes. Sub-
sequently the samples were analyzed as described above. According to the 
dilution factor, the lower limit of sensitivity rose to 0.2 ng/ml for this 
procedure. This method, described by Valdes et al. ( 127) results in the release 
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of the digoxin-like substance from its protein binding, thus enhancing 
measured immuno-activity. 
In the patients with subarachnoid hemorrhage, serum samples were taken on 
admission (day 0) and after six days, always before plasma volume deter-
minations. We also assayed serum samples from healthy volunteers and 
newborn infants (128). 
Plasma volume determination 
All patients underwent plasma volume determinations on admission and 
again on the sixth day. Plasma volume was determined by the isotope dilu-
tion technique with 1311 labeled to human serum albumin as described in 
detail in Chapter III. We expressed the results in total plasma volume and 
calculated the percentage of change between the two measurements. We 
considered only a decrease of more than 10% to be substantial. 
Ventricular size, amount and site of hemorrhage 
As a linear measurement of ventricular size, we used the bicaudate index, 
that is the width of the frontal horns at the levels of the caudate nuclei divided 
by the corresponding diameter of the brain. The width of the third ventricle 
was measured on the slice where the third ventricle had the maximal 
transverse diameter. The bicaudate index and width of the third ventricle 
were converted into a relative size by dividing the absolute values by the 
upper limit for age (134, Chapter V). An intraventricular hemorrhage was 
considered to be frank when at least one ventricle was completely filled with 
blood. 
The amount of cisternal hemorrhage was graded separately for each of the 
following cisterns on a scale ofO to 3 (0 =no blood, 1 =sedimentation of red 
blood cells in a cistern, 2 = cistern or fissure partly filled with blood, 3 = 
cistern or fissure completely filled with blood): frontal interhemispheric 
fissure, quadrigeminal cistern and paired suprasellar cisterns, ambient 
cisterns, basal sylvian fissures and lateral sylvian fissues (56, 134). The site of 
the hemorrhage was classified into two main groups: subarachnoid blood 
with the center of the hemorrhage located in the frontal interhemispheric 
fissure (12 patients), and subarachnoid blood with the center of blood 
unilaterally in suprasellar cistern, sylvian fissure or ambient cistern (13 
patients) (131). The admission CT scans were graded without knowledge of 
the results of the digoxin immunoassay. 
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RESULTS 
Digoxin immunoassay values 
All samples measured before heating contained values below the detection 
limit, except for the plasma of the newborn infants, which contained a 
digoxin-like substance in all cases (range 0.2-0.4, mean 0.3 ng/ml). 
After heating, the plasma values for digoxin-like substance from 17 healthy 
volunteers contained no detectable digoxin in 16; in one the value was 0.2 
ng/ml. In all four newborn infants digoxin-like substance was found and 
ranged from 0.3 to 0.8 ng/ml (mean 0.5 ng/ml). Eleven of the 25 patients 
with SAH had detectable digoxin-like substance on admission. The values 
ranged from 0.2 to 0.5 ng/ml (mean 0.4 ng/ml). On second measurement 
(day 6 after admission), 17 had detectable digoxin-like substance; the values 
ranged from 0.2 to p.8 ng/ml (mean 0.4 ng/ml). Ten of the 25 patients with 
SAH had detectable levels in both samples, 8 in only one sample and in 7 
patients the samples were negative on both occasions (Figure 1) . 
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Figure l. Digoxin-like substance values in 25 patients with a ruptured aneurysm. 
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Digoxin-like substance and relation with blood pressure, fluid and sodium intake 
We investigated if hypertension after the hemorrhage or the intake of fluid 
and sodium might have caused the presence of the digoxin-like substance on 
the sixth day after admission. The incidence of hypertension was not signifi-
cantly different between patients with detectable digoxin values (9/17 or 
52%) and patients without detectable digoxin values (6/8 or 75%) (p > 0.1 ). 
Blood urea nitrogen and creatinine levels remained within normal limits in 
all patients. 
Sodium intake ranged from 205 to 1355 mmol (mean 586 mmol) in 
digoxin-positive patients and from 135 to 850 mmol (mean 609 mmol) in 
digoxin-negative patients (Mann-Whitney, p > 0.1 ). 
Fluid intake, cumulative over five days, ranged from 8.4 to 13.9 liters 
(mean 10.9) in digoxin-positive patients and from 10.6 to 15.9liters (mean 
12.0) in digoxin-negative patients, which is not significantly different (Mann-
Whitney, p > 0.1). 
Fluid balance was similar in both groups of patients. The values of the 
cumulative fluid balance ranged from -0.6 to 7.0 liters (mean 4.0 liters) in 
digoxin-positive patients and from -0.9 to 7.0 liters (mean 4.0) in patients 
without digoxin-like substance. No atrial arrhythmias were observed in any 
of the patients. 
Digoxin-like substance, sodium balance and volume depletion 
Given the result that the presence of a digoxin-like substance on day 6 could 
not be explained by differences in blood pressure or in intake of water and 
sodium, the next question was whether the substance itself (on day 0 or 6) 
may have contributed to changes in sodium balance and plasma volume. A 
negative cumulative sodium balance over five days was found in 14 (78%) of 
the 18 patients who had a detectable digoxin-like substance in one or two of the 
plasma samples, and in 3 of the 7 patients (43%) who had no detectable values 
in the two samples. This difference did not reach statistical significance 
(Fisher's exact test, p 2 = 0.1 ). The cumulative sodium balance values ranged 
from -72 mmol to -179 mmol (mean -169 mmol) in the 14 digoxin-positive 
patients and froin + 110 to -370 mmol (mean -53 mmol) in digoxin-negative 
patients (Mann-Whitney, p > 0.1). 
The plasma volume decreased more than 10% in 12 of the 18 digoxin-positive 
patients (67%) and in 3 of the 7 digoxin-negative patients (43%), Fisher's 
exact test, p > 0.1 ). 
Digoxin-like substance and relation with clinical and CT features 
The Table shows the occurrence of unconsciousness at the time of hemor-
rhage, Glasgow Coma Score (120) on admission, enlargement oflateral and 
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Table. Clinical and CT features in 25 patients with and without digoxin-like substance 
following subarachnoid hemorrhage. 
Clincal 
and 
CT features 
Loss of consciousness at ictus 
Glasgow Coma Score 
Enlarged lateral ventricles 
Enlarged third ventricle 
Frank intraventricular 
hemorrhage 
Amount of cisternal 
hemorrhage* 
Site of subarachnoid blood* 
center of hemorrhage in 
frontal interhemispheric 
fissure 
center of hemorrhage in 
other cisterns or fissures 
*p < 0.02. 
< 12 
12, 13 
14 
0-5 
6-10 
ll-15 
16-20 
21-25 
26-30 
No. of patients (%) 
Digoxin-like 
substance 
(n = 18) 
6 
2 
3 
13 
5 
!0 
5 
I 
4 
6 
4 
3 
0 
II 
7 
(33) 
(II) 
(17) 
(72) 
(28) 
(56) 
(28) 
(6) 
(22) 
(33) 
(22) 
(17) 
(61) 
(39) 
No digoxin-like 
substance 
(n=7) 
3 
0 
0 
7 
0 
2 
2 
I 
4 
2 
0 
0 
0 
6 
(43) 
(100) 
(29) 
(29) 
(14) 
(57) 
(29) 
(14) 
(86) 
third ventricles and the presence offrank intraventricular hemorrhage on the 
initial CT scan for patients with and without digoxin-like substance. Patients 
with digoxin-like substance more often had an impaired level of conscious-
ness on admission and enlarged lateral and third ventricles on tl:le first CT 
scan, but none of these differences reached statistical significance. 
The amount of cisternal blood on the initial CT scan was significantly 
associated with the presence of digoxin-like substance (Mann-Whitney test, 
p < 0.02). 
Predominance of subarachnoid blood in the interhemispheric fissure, 
suggesting rupture of an anterior communicating artery, was significantly 
associated with the presence of digoxin-like substance (Fisher exact test p2 = 
0.02). Angiography or autopsy was performed in 10 of the 12 patients with 
subarachnoid blood mainly located in the frontal interhemispheric fissure on 
CT, and an aneurysm of the anterior communicating artery was demon-
strated in all (Figure 2).Angiography or autopsy was done in 12 of the 13 
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Figure 2. Computed tomogram of a patient with diffusely distributed blood with the center of 
the blood located in the frontal interhemispheric fissure (solid arrow), near the hypothalamus 
(open arrow). The digoxin values were 0.4 ng/ml on admission and 0.6 ng/ml on the 6th day. 
patients with the center of the hemorrhage in other cisterns or fissures, and a 
differently located aneurysm was demonstrated in all (five aneurysms of the 
middle cerebral artery, five aneurysms of the carotid artery and two 
aneurysms at the basilar bifurcation). 
DISCUSSION 
Before the description of the syndrome of inappropriate antidiuretic 
hormone (SIADH) (7, 27, 61, 110), natriuresis after SAH was attributed to a 
putative natriuretic factor. This was termed cerebral salt wasting (21, 95, 
144). Our findings demonstrate that after SAH a digoxin-like natriuretic 
factor circulates and that its release is related to cerebral factors such as the 
amount and the site of the hemorrhage. Factors which are known to be 
associated with the presence of this substance in plasma, such as hypertension 
(26), fluid and salt loading (39, 46), were similarly distributed between the 
groups of patients with and without digoxin-like substance, and in none of the 
patients renal failure (44) or atrial arrhythmias (64) could account for the 
reaction to digoxin antibodies. The presence ofthis substance was associated 
with extensive cisternal hemorrhage and with a distribution of blood 
suggesting rupture of an anterior cerebral artery aneurysm. These findings 
suggest that in patients with subarachnoid hemorrhage a cerebral factor is 
responsible for the release of a digoxin-like substance. 
In patients with subarachnoid hemorrhage, digoxin-like substance could 
be detected only after heating of the plasma. In the control group, consisting 
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of healthy hospital personnel, heating of the plasma samples revealed a very 
low value in only one subject. The levels in patients with subarachnoid 
hemorrhage were in the range of the values observed in newborn infants, 
which suggests that these findings have pathological significance. 
Digoxin-like substance appears to have natriuretic properties, as was 
demonstrated in salt-loaded healthy subjects and in untreated hypertensive 
patients (26, 39, 66, 97). Further evidence for its natriuretic activity was 
found in studies showing the inhibition of membrane-bound sodium-
potassium ATP-ase leading in turn to inhibition of sodium reabsorption in 
the renal tubule (72). Our results also suggest an association between digoxin-
like substance and natriuresis, but this association did not reach statistical 
significance. A similar association was found between digoxin-like substance 
and volume depletion. 
Natriuresis after SAH is a clinically important phenomenon, since it is 
associated with volume depletion (Chapter III), which plays a role in the 
development of cerebral ischemia (113). 
Cerebral ischemia is one of the major complications after subarachnoid 
hemorrhage. It is traditionally attributed to vasospasm, but not all patients 
with vasospasm develop ischemia (53). It might be that hypovolemia 
increases blood viscosity and that this, in combination with vasospasm, may 
lead to an impaired cerebral blood flow and cerebral ischemia. This is 
supported by the observation that cerebral ischemia may be successfully 
treated by volume expansion (23, 98, 116) and that the incidence of cerebral 
ischemia increases if fluid restriction is applied to correct hyponatremia 
(Chapter II). 
We found that the presence of a digoxin-like substance was associated with 
an extensive subarachnoid hemorrhage and also with an aneurysm of the 
anterior communicating artery. In both these conditions lesions of the hypo-
thalamus have been described (22) and it might be that hypothalamic lesions 
are the crucial factor in the release of digoxin-like substance. It is not unlikely 
that the human hypothalamus contains a digoxin-like substance, as this has 
been demonstrated in the ox and guinea pig (35, 51). An alternative 
explanation of the relation between blood in the interhemispheric fissure and 
the release of a digoxin-like substance involves not only the hypothalamus, 
but also the heart. Areas of myofibrillar degeneration in the heart have been 
shown in association with hypothalamic lesions after SAH (29). Therefore, a 
ruptured anterior aneurysm or a large hemorrhage might result in a 
hypothalamic lesion which would then lead to myofibrillar degeneration in 
the heart by which a digoxin-like substance is released. 
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Chapter VII 
THE EFFECT OF FLUDROCORTISONE ACETATE 
ON PLASMA VOLUME AND NATRIURESIS 
INTRODUCTION 
In a previous study we demonstrated that a decrease in plasma volume of 
more than l 0% occurs in approximately 50% of patients with aneurysmal sub-
arachnoid hemorrhage (SAH) (Chapter III). This hypovolemia is considered 
harmful because it might precipitate cerebral infarction (ll3, Chapters II 
and III). The cause of the hypovolemia has been a matter of debate. 
Although bed-rest and daily blood sampling could lower plasma volume, 
these effects cannot account for the hypovolemia, because the total amount of 
blood withdrawn for diagnostic laboratory tests was approximately 140 ml 
and bed-rest does not usually decrease the plasma volume by more than 10% 
(45, ll2). A better explanation is that volume depletion after SAH is caused 
by natriuresis (21, 95, Chapter III). 
Hypovolemia might be treated by increasing salt intake, but this only 
further enhances sodium excretion (99). Therefore, it would be more appro-
priate to prevent volume depletion by diminishing renal sodium excretion. 
Fludrocortisone acetate has mineralocorticoid activity and enhances distal 
tubular sodium reabsorption in the kidney. In order to investigate the 
feasibility of this approach a pilot study was performed of the effect of 
fludrocortisone acetate on plasma volume, sodium balance, renin values, and 
on the incidence of medical complications such as hypokalemia and cardiac 
failure. 
PATIENTS AND METHODS 
Patients 
We prospectively studied a consecutive series of 39 patients with signs and 
symptoms of subarachnoid hemorrhage and with computed tomographic 
evidence of blood in the basal cisterns, in the absence of lesions other than 
aneurysms that might cause subarachnoid hemorrhage (130, 133). 
All patients were admitted within 48 hours of the initial hemorrhage. 
Patients with any of the following conditions were excluded: endocrine dis-
turbances, heart failure, renal failure, neoplasm or treatment with diuretic 
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drugs before admission or during the study. Patients over 70 years of age were 
excluded, because of the risk of heart failure during the treatment protocol. 
None of the patients was treated with steroids or antifibrinolytic agents. 
Eighteen of the 39 patients admitted to the study were excluded. The 
reasons for exclusion were: arteriovenous malformation (2 patients)' negative 
angiography in 9 patients (in 5 of these 9 patients a negative angiography was 
predicted from CT, with a predominantly perimesencephalic hemorrhage 
(133)), fatal rebleed before the second plasma volume determination (3 
patients), heart failure (2 patients), and incomplete sodium balance data due 
to urinary incontinence (2 patients). 
In 19 of the remaining 21 patients an aneurysm was demonstrated. In two 
patients angiography was not performed, because surgical treatment was felt 
to be precluded by an impaired level of consciousness. However, rupture of 
an aneurysm was highly probable because of the pres~nce of blood in the 
basal cisterns, without evidence of another lesion or subarachnoid hemor-
rhage of the perimesencephalic type (130, 133). 
On admission eleven of the 21 patients had a maximal Glasgow Coma score 
of 14, eight patients had a Glasgow Coma score of 12 or 13, one had a 
Glasgow Coma score of 7, and one of 5. 
During the study period, which lasted 12 days, all patients were under 
continuous observation in an intensive care unit. CT was performed on 
admission and was repeated if a patient's clinical condition deteriorated. We 
obtained daily measurements of electrolytes, blood urea nitrogen, serum 
osmolality and hematocrit. 
The mean blood pressure was calculated from four blood pressures taken at 6-
hour intervals at 6, 12, 18 and 24 hours. Hypertension was defined as an 
average mean blood pressure (diastolic value + 1/3 of the pulse pressure) of 
120 or more on at least one day. 
Hyponatremia was defined as a sodium level lower than 135 mmol/L on at 
least two consecutive days (Chapter II). The calculations of sodium balance 
and the determination of plasma volume with 1311 labeled to human serum 
albumin were performed according to previous descriptions (Chapter III). 
Plasma renin concentration was measured with a radioimmunoassay as 
described elsewhere (25). 
Treatment with fludrocortisone acetate was always started within 48 hours of 
the hemorrhage, in a dose of 0.2 mg twice a day intravenously, in 200 ml 
glucose 5%. All patients had a fluid intake of at least 3,000 ml per 24 hours. 
Treatment was discontinued on the 12th day, at the time of operation (10 
patients, usually on the 12th day) or when patients developed overt heart 
failure. 
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RESULTS 
Hyponatremia and changes in plasma volume 
Hyponatremia developed in four of the 21 patients, on days2, 3, 3 and 4 after 
admission. In these four patients serum sodium levels dropped to 128, 131, 
131 and 133 mmol per liter. The sodium values returned to normalS, 2, 2 and 
4 days later, respectively. In these patients the plasma volume decreased 
more than 10% in three and 8% in the fourth. Of the 17 patients in whom 
sodium levels remained normal, plasma volume decreased with 16% in one, 
decreased less .than 10% in four, incntased from 1 to 10% in seven, increased 
from 11 to 20% in two, and increased considerably in three (23%, 33% and 
SO%, Figure 1). 
Sodium balance 
The individual sodium balance charts and cumulative sodium and fluid 
balance data are summarized in Figures 1 and 2. A negative sodium balance 
preceded the development of hyponatremia in three of the four patients. In 
four of the 17 patients with continuously normal sodium values, the sodium 
balance was also negative. 
The cumulative sodium intake over five days was higher in patients with a 
positive sodium balance (range 680 to 1090 mmol, mean 888 mmol) than in 
patients with a negative sodium balance (range 220 to 94S, mean 674), but 
this difference did not reach statistical significance (Mann-Whitney O.OS < p 
< 0.1). 
Plasma volume decreased with more than 10% in three of the seven patients 
with a negative sodium balance and in only one of the 14 patients with a 
positive sodium balance. This difference reached statistical significance only 
on one-sided testing, in keeping with our previous hypothesis (Fisher's exact 
test, p1 = 0.04, p2 = 0.08). 
Renin values were measured in samples from IS patients treated with 
fludrocortisone acetate and in. stored samples from 18 previous patients not 
treated with fludrocortisone acetate. 
Of the IS patients from the present series, six developed a negative sodium 
balance; these six had renin levels ranging from 2.4 to 23.7 J.t.U/ml (mean 10.6 
uU/ml) on admission, and from l.S to 34.4 J.t.U/ml (mean 10.4J.t.U/ml) on 
second measurement (6 days after admission). In the nine patients with a 
positive sodium balance the values were 0.6 to 21.2 j.t.U/ml (mean 8.8 J.t.U/ml 
and 1.1 to 13 j.t.U/ml (mean S.9 pU/ml), respectively (figure 3). 
The stored plasma samples of the 18 patients from a previous study (Chapter 
III) were assayed together with the samples of the IS patients of the current 
study. The renin values in patients who developed a negative sodium balance 
ranged from S.3 to 66.1 J.t.U/ml (mean 22.4 J.t.U/ml) on admission and 
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Figure l. Sodium balance in patients with a decrease in plasma volume of more than l 0% 
or between 0 and 10%. (stars= data expressed in mmol; circles= data expressed in liters). 
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Figure 2. Sodium balance in patients with an increase in plasma volume. (stars = data 
expressed in mmol; circles = data expressed in liters) 
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increased substantially after 6 days (range 2.8 to 136.2 1-LU/ml, mean 49.5 
1-LU/ml). Patients with a positive sodium balance had renin values ranging 
from 5.8 to 23.7 1-LU/ml (mean 12.1 1-LU/ml) on admission and from 3.7 to 
282.6 1-LU/ml) on second measurement. 
The changes in renin values are summarized in Figure 3. A substantial 
increase in renin values was observed particularly in patients with a negative 
sodium balance who were not treated with fludrocortisone acetate. With two 
exceptions, the renin values showed no appreciable change in the other 
patients. 
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Figure 3. Plasma renin values in 15 patients with SAH treated with fludrocortisone acetate 
and in 18 patients without fludrocortisone acetate treatment (from a previous study (Chapter 
III)), related to cumulative sodium balance. 
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Medical and neurological complications of treatment 
In three ofthe original39 patients pulmonary edema developed (8%), treated 
successfully by diuretics. In two patients hypoxia associated with pulmonary 
edema developed within six days of admission. These patients were excluded 
from a second plasma volume determination, because diuretic treatment was 
necessary. In one patient neurogenic pulmonary edema was observed on 
admission. Because a rapid improvement occurred within 24 hours after 
artificial ventilation, this patient was included as yet. However, on the 7th 
day of admission a relapse of pulmonary edema occurred. Plasma volume 
had increased with 50%. 
In four of the 21 patients, hypokalemia developed (range 3.1 to 3.4 
mmol/L, mean 3.3 mmol/L), but this was easily corrected by the administra-
tion of potassium chloride intravenously. 
Eight of the 21 patients (38%) had a raised mean blood pressure of more 
than 120 mm Hg. In five of these eight patients plasma volume had increased, 
which occurred in a similar proportion (7 ofl3) in patients with normal blood 
pressures. None of these eight patients developed a deterioration that could 
be attributed to these high blood pressures. 
Eight of the 21 patients developed a clinical deterioration: six from re-
bleeding and two from cerebral infarction; in all episodes the diagnosis was 
confirmed by CT scanning. Plasma volume increased from 6 to 33% (mean 
13%) in four of the six patients with a rebleed, which was not significantly 
different from plasma volume increase in patients without a rebleed (8 of 15 
patients, range 1-50%, mean 15%). 
DISCUSSION 
The results of this study suggest that fludrocortisone acetate in the dosage we 
used, together with adequate salt intake, may limit the occurrence of 
hypovolemia in patients with SAH. The plasma volume decreased more than 
10% in 4 of the 21 patients, against 11 of the 21 in our previous study (Chapter 
III). Although the two series of patients were not studied in a parallel fashion, 
the medical management other than treatment with fludrocortisone was the 
same. Comparison of the degree of plasma volume changes showed a 
statistically significant difference in favor of treatment with fludrocortisone 
(Figure 4). Moreover, in the study of Solomon et al., 44% of the patients 
(11/25) had a decreased blood volume (113), which is similar to our series 
without fludrocortisone (Chapter III). In keeping with the volume status, the 
cumulative sodium balance was negative in only 7 of21 patients, against 14 of 
21 in our previous study (Chapter III), and renin values were lower in 
patients who were treated with fludrocortisone (Figure 3). 
An important question in this preliminary study was whether patients 
treated with fludrocortisone suffer side effects which would preclude this 
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Figure 4. Plasma volume changes in 21 patients with a ruptured aneurysm treated with fludro-
cortisone acetate compared with patients without fludrocortisone acetate treatment from our 
previous study (Chapter III). (Mann-Whitney, p < 0.04). 
treatment in SAH. In three of 39 patients (8%), signs of pulmonary edema 
developed, but this could be easily reversed by diuretic treatment. In one of 
these three patients, pulmonary edema had already been present on 
admission and in retrospect this patient should not have been included in the 
study. Low serum potassium values were observed in only four patients after 
the administration of fludrocortisone, but these were easily corrected. 
Volume expansion in patients with SAH may in theory increase blood 
pressure with an increased risk of rebleeding. In this small series of patients 
the incidences of both hypertension and rebleeding were unchanged when 
compared with our previous study. 
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Volume depletion in SAH is considered clinically important, because 
patients with vasospasm have a higher risk of developing cerebral ischemia if 
they are volume-depleted (113). This is supported by the observation that 
patients who developed hyponatremia and were fluid-restricted had an 
increased risk of cerebral ischemia (Chapter II). Moreover, several reports 
suggest that cerebral ischemia can be reversed by the use of volume 
expanders (63, 98, 116). The use of volume expanders and also of induced 
hypertension in patients who have developed signs of cerebral ischemia is not 
without risks and not easy to carry out. Kassell et al. demonstrated that such 
measures are accompanied in 2()% of cases by side effects such as overhydra-
tion; 5% had clotting abnormalites (63). Recently, Finn et al. recommended 
the use of Swan Ganz catheters to control the volume status in SAH patients 
(33). 
We think it worthwhile to try and prevent volume depletion by inhibiting 
excessive sodium excretion instead of treating volume depletion after signs of 
cerebral ischemia have already developed. That fludrocortisone can increase 
plasma volume by inducing sodium retention has been demonstrated in other 
clinical situations (19, 124). The present study suggests that fludrocortisone 
treatment is a relatively simple and safe method of decreasing the incidence of 
volume depletion and sodium loss in patients with SAH. Obviously, this has 
to be confirmed in a study with concurrent controls, which we have now 
embarked upon. Moreover, it remains to be established that these measures 
result in a decreased incidence of cerebral ischemia, one of the major compli-
cations after SAH (53). 
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GENERAL DISCUSSION 
This study focuses on hyponatremia following aneurysmal subarachnoid 
hemorrhage. Hyponatremia is often explained by the syndrome of in-
appropriate secretion of antidiuretic hormone (SIADH). In that case, 
sustained secretion of antidiuretic hormone is maintained in the face oflow 
serum osmolality and an expanded extracellular fluid volume, which in turn 
causes hyponatremia and natriuresis. Recently, however, it has been 
questioned whether inappropriate secretion of ADH really occurs after SAH, 
since decreased blood volumes have been demonstrated in patients with 
hyponatremia, although they fulfilled the laboratory criteria for SIADH. 
This doubt was corroborated by our retrospective review of a consecutive 
series of patients, which demonstrated that hyponatremia and fluid restric-
tion were associated with an increased risk of cerebral infarction (Chapter II). 
Blood volumes in the earlier study had been measured only once, when 
hyponatremia had occurred. In our prospective study we could demonstrate 
that the plasma volume decreases in patients who develop hyponatremia by 
comparing two measurements, one on admission and one after five days. In 
addition, we measured sodium balance, body weight, and secretion of 
antidiuretic hormone (vasopressin) and renin. Hyponatremia was associated 
with a decrease in plasma volume and a decrease in body weight, and it was 
preceded by a negative sodium balance in all instances. Serum vasopressin 
levels were increased or normal on admission, but had decreased at the time 
of hyponatremia. Conversely, plasma renin values increased between the two 
measurements. An additional find-ing was that plasma volume considerably 
decreased also in some patients with normal sodium levels, usually as a result 
of excessive natriuresis (Chapter III). 
All these findings support the concept of salt wasting and negate the 
syndrome of inappropriate ADH secretion. These observations confirmed 
experiments in monkeys, which clearly showed the development of a negative 
salt balance before hyponatremia occurred. In the fifties, before the SIADH 
had been described, hyponatremia in various neurological disorders was also 
attributed to cerebral salt wasting. In that concept a cerebral factor was 
responsible for the release of a putative natriuretic hormone. After we had 
demonstrated that hyponatremia after SAH is caused by excessive natriure-
sis, we investigated if a substance which possessed natriuretic properties could 
be detected in plasma of patients with SAH. At that time the so-called atrial 
natriuretic peptide could be detected only in tissues and not in plasma. 
Another natriuretic substance, the digoxin-like immunoreactive substance 
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could actually be measured in plasma, was identified in 61% ofthe patients 
with an aneurysmal SAH and was, although not significantly, associated 
with natriuresis and volume depletion (Chapter VI). In the mean time assays 
have been developed by which the atrial natriuretic peptide can be measured 
in plasma. At present we are investigating if these substances circulate after 
SAH. 
What cerebral factor causes the release of the digoxin-like substance is 
uncertain. We found an association between the presence of this substance 
and the site of the ruptured aneurysm at the anterior communicating artery, 
and also between hyponatremia on the one hand and an enlarged third 
ventricle and intraventricular blood on the other (Chapter VI). These 
findings can make some sense if we assume that an enlarged third ventricle, 
intraventricular blood and a ruptured anterior aneurysm may all result in 
damage of the hypothalamus. Similarly, an extensive extravasation ofblood 
which was also related with the presence of the digoxin-like substance, may 
contribute to hypothalamic damage. Hypothalamic damage may directly 
result in the release of a local natriuretic substance. Another possibility is that 
hypothalamic damage has an effect on the heart, which results in the release of 
these substances from the myocardium via monoamines or.other humoral 
factors. If this last hypothesis were true, there should be an association 
between ECG changes or CPK levels and the presence of natriuretic 
substances. This is also under current investigation. 
Hyponatremia following aneurysmal SAH is of clinical importance. In our 
retrospective study, hyponatremia developed between the second and the 
tenth day after the initial hemorrhage. A striking finding was that secondary 
deteriorations could not be attributed to hyponatremia alone, probably 
because hyponatremia developed gradually and serum sodium levels did not 
fall below 120 mmol/L. But when a clinical deterioration occurred after 
hyponatremia, it was invariably caused by cerebral infarction (Chapter II). 
In these patients fluid restriction was applied to correct low sodium levels. 
Since we now know that patients with hyponatremia have decreased plasma 
volume levels, this treatment must have aggravated a hypovolemic state. 
This is especially dangerous at a time when these patients are at risk of 
developing cerebral ischemia, the more so since evidence is accumulating 
that cerebral ischemia can be reversed by hypervolemia. How hypovolemia 
causes cerebral ischemia is unclear, but a likely explanation is that 
hypovolemia is associated with an increased blood viscosity, which may 
result in impaired cerebral perfusion. Measurement of blood viscosity and of 
cerebral blood flow and metabolism might elucidate this problem. 
The volume status in patients with SAH is extremely important. In the 
maintenance of this volume status two approaches are possible. From the 
onset of the hemorrhage an intake of 3 to 3.5 liters fluid can be prescribed. If 
cerebral ischemia develops despite these measures, extra fluid albumin or 
dextran can be given until the central venous pressure is about 12. It has been 
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advised to control this extra fluid intake by Swan Ganz catheter monitoring. 
We have tried to prevent a negative fluid balance by the administration of 
extra sodium solutions or of albumin. In some of these patients the fluid 
balance remained negative, because the increased fluid intake was followed 
by a proportionally increased fluid excretion. 
A second approach could be to prevent hypovolemia by inhibition of 
sodium excretion. In a pilot study (Chapter VII) we demonstrated that 
fludrocortisone in the dosage we administered is comparatively safe and that 
the results on plasma volume and natriuresis are encouraging. Further 
studies are needed to confirm these results in a comparison with concurrent 
controls and to demonstrate that these measures result in fewer cerebral 
infarcts. 
Another attempt to prevent cerebral ischemia is by means of induced 
hypertension. The most important hazard of induced hypertension in 
patients with an unclipped aneurysm is rebleeding. Conversely, review of the 
same consecutive series of patients described in Chapter II showed that 
patients who presented with hypertension and were treated with antihyper-
tensive drugs, had a significantly higher incidence of cerebral infarction 
(Chapter IV). Surprisingly, average blood pressures were still higher in 
patients treated with antihypertensive drugs, and hyponatremia occurred 
more often (although not significantly). The results are difficult to explain. 
Hypertension or antihypertensive drugs might perhaps inhibit the fibrinolyt-
ic system, but such an effect has not yet been reported. Another possibility is 
that hypertension is related to vasospasm, perhaps· as a compensatory 
response. This hypothesis might be tested by investigating the relation 
between blood pressure and vasospasm, for instance by means of serial 
transcranial ultrasound techniques. 
Cerebral ischemia is a devastating complication after SAH. Our studies 
showed that volume status and blood pressure play an important role in the 
development of cerebral ischemia. The task ahead is to assess the effect of 
optimal management of blood volume and blood pressure on rebleeding-
that other great risk - and on the general outcome of patients with aneurysmal 
subarachnoid hemorrhage. 
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SUMMARY 
The aim of this study was to investigate if and why patients with 
subarachnoid hemorrhage (SAH) and hyponatremia have a poor outcome, 
how hyponatremia develops and how it can be prevented. 
In Chapter I the natural history and complications after SAH are 
discussed. Aneurysmal SAH has an incidence of between 11 and 19 per 
100,000 inhabitants per year. It is a severe disorder with high mortality and 
morbidity. As'a result of the initial bleeding about a third ofthe patients will 
die or become severely disabled. These patients are probably beyond the 
influence of medical or surgical treatment. However, it has been suggested 
that many destructive hemorrhages are preceded by minor warning bleeds 
and that the majority of these patients can be saved if these warning bleeds 
are recognized. 
Half of the patients who survive the initial hemorrhage in a good clinical 
condition subsequently die or become incapacitated by complications that 
occur especially during the first weeks after the hemorrhage. In patients who 
are admitted, the aim of the management is to prevent these serious 
complications. 
In part 2 of Chapter I, the neurological complications are reviewed. 
Rebleeding and cerebral infarction are the two major factors that influence 
the outcome of patients following SAH. The overall outcome of patients who 
rebleed is poor, as 82% will die within three months. The peak incidences of 
rebleeding are at the end of the second and third weeks and probably on the 
first day. Rebleeding can be prevented by clipping of the aneurysm. The 
timing of surgery, early- within 72 hours- or delayed, and the selection of 
patients who should be operated on are major points of controversy. 
Tranexamic acid considerably decreases the risk of rebleeding, but the 
outcome of the patients does not improve, because of a concomitant 'increase 
in the incidence of cerebral infarcts. Therefore, antifibrinolytic treatment is 
not beneficial unless cerebral ischemia can be prevented. 
Cerebral infarction occurs in about 27% of the patients. The ischemic 
lesions are multifocal, mainly in cortical areas and boundary zones. Cerebral 
ischemia develops gradually. Most patients have focal deficits, but a decrease 
in consciousness preceded this and can ·be the only sign. Many therapeutic 
measures have been tried: especially volume expansion and induced 
hypertension might be beneficial. 
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Acute hydrocephalus occurs in 20% of the patients who are admitted early 
after the hemorrhage, at least if there is no referral bias with the selection of 
patients in good clinical condition. The immediate effect of shunting on the 
level of consciousness is impressive, but nevertheless a larger percentage die 
from rebleeding and cerebral infarction. Careful techniques of drainage 
might improve the outcome. 
The medical complications are discussed in part 3. Electrocardiographic 
abnormalities associated with an elevation of serum cardiac enzymes are fre-
quently seen after SAH. Diffuse myofibrillar degeneration accounts for these 
EGG changes. However, of all acute cardiorespiratory complications, most 
are. primary disorders of respiratory rhythm and not cardiac arrythmias. 
Neurogenic pulmonary edema is a dramatic complication, but mortality has 
decreased by the introduction of positive end-expiratory pressure (PEEP). 
Hypertension frequently develops in patients with SAH who did not have 
a previous history of hypertension. Treatment of hypertension immediately 
following the acute event is an important dilemma. Hypertension might 
increase the incidence of re bleeding or aggravate cerebral ischemia by edema 
formation. On the other hand, lowering the blood pressure might result in 
cerebral ischemia by impairing cerebral perfusion. Less common medical 
complications are gastrointestinal bleeding, septicemia and hyperglycemia. 
In part 4, sodium homeostasis and causes of hyponatremia are reviewed. 
Originally hyponatremia in SAH was attributed to a putative natriuretic 
hormone that caused true sodium depletion. This phenomenon was termed 
cerebral salt wasting. After the syndrome of inappropriate secretion of 
antidiuretic hormone (SIADH) was defined, hyponatremia after SAH has 
generally been attributed to SIADH. In SIADH the osmotic receptors 
function inappropriately, which results in a sustained secretion of antidiuret-
ic hormone. This leads to an increase in the extracellular volume with 
subsequent hyponatremia and natriuresis. To reverse this dilutional hypo-
natremia, fluid restriction is recommended. But fluid restriction may be 
harmful rather than beneficial if hyponatremia is after all associated with 
volume depletion, because fluid restriction may aggravate a hypovolemic 
state leading to hemoconcentration and changes in blood viscosity. This may 
be especially dangerous in patients with vasospasm who already have an 
impaired cerebral perfusion. If this were true, it is to be expected that patients 
with hyponatremia who were treated with fluid restriction were at a higher 
risk of developing infarcts. Therefore, we studied the relationship between 
hyponatremia and cerebral infarction. 
The results of this study are described in Chapter II. In a series of 134 
consecutive patients with SAH, 44 patients had sodium levels below 135 
mmol per liter on at least two consecutive days. Hyponatremia developed 
between the second and the tenth day after the hemorrhage. Severe 
hyponatremia (sodium level of 120 to 124 mmol/L) occurred in only 6 of the 
44 patients. Twenty-five of the 44 patients fulfilled the laboratory criteria of 
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SIADH, twelve had other conditions that might have contributed to 
hyponatremia (sepsis, severe vomiting, renal disease, Addison's disease and 
diuretics). In seven patients the cause remained unknown because of 
incomplete laboratory investigations. The incidence of cerebral infarction as 
well as mortality from cerebral infarction was found to be significantly higher 
in patients who developed hyponatremia. None of the episodes of clinical 
deterioration could be attributed to hyponatremia alone, without signs of 
cerebral ischemia. 
Twenty-six of the 44 patients with hyponatremia had been treated with 
fluid restriction to correct the serum sodium levels and cerebral infarcts 
developed in 21. It appears that fluid restriction to correct hyponatremia is 
potentially dangerous in patients with SAH. This observation indirectly 
supported the notion that hyponatremia was caused by salt wasting. 
To elucidate the cause of hyponatremia in SAH - sodium dilution or 
sodium depletion - a prospective study was performed on plasma volume, 
sodium balance and secretion of antidiuretic hormone in 21 patients with 
aneurysmal SAH (Chapter III). In ll of the 21 patients, the plasma volume, 
measured by an isotope dilution technique, decreased rr:ore than 10%. This 
was accompanied by a negative sodium balance and hyponatremia in six 
patients, a negative sodium balance without hyponatremia in four patients, 
and a positive sodium balance in one patient. Together with a decrease in 
plasma volume, blood urea nitrogen content increased and body weight 
decreased. Serum vasopressin values were elevated on admission and 
declined in the first week in all patients, regardless of the presence of 
hyponatremia. 
These findings are consistent with a salt wasting syndrome rather than 
with inappropriate secretion of antidiuretic hormone. This study confirms 
that patients with SAH have volume depletion and natriuresis and ought to 
be treated with volume expansion. Maintenance of an adequate intravas-
cular volume is important in the management of patients with SAH. Patients 
with SAH are threatened by vasospasm, which may lead to cerebral 
ischemia. Cerebral blood flow may be fJrther impaired in patients with 
volume depletion through an increased blood viscosity. The effectiveness of 
volume expansion in increasing cerebral perfusion may be explained by an 
improvement in blood viscosity or a risein cardiac output. The importance of 
an adequate intravascular volume has been corroborated by reports 
describing improvements of clinical deficits attributed to cerebral ischemia 
after volume expansion. 
Another method of preventing the development of cerebral ischemia 
might be to increase blood pressure. This has been suggested by investigators 
who used induced hypertension in patients with symptomatic vasospasm and 
in this way produced relief of ischemic symptoms. This might mean that high 
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blood pressure after SAH prevents cerebral ischemia and therefore ought not 
to be treated with antihypertensives. On the other hand, if high blood 
pressure is not lowered after the initial bleeding, this might result in an 
increased incidence of rebleeding. 
We investigated in a consecutive series of 134 patients with aneurysmal 
subarachnoid hemorrhage if institution of antihypertensive treatment was 
related to the incidence of cerebral ischemia and rebleeding. The aim of 
hypertensive treatment was to reduce the diastolic blood pressure to levels 
below 110 mm Hg. There was no difference in outcome between patients 
with and without antihypertensive drugs. 
Rebleeding was less frequent in patients with antihypertensive treatment 
(12/80 patients (15%), versus 18/54 patients (33%) without antihypertensive 
treatment (p = 0.012)). Nevertheless, patients with antihypertensive treat-
ment had, on average, still higher blood pressures than untreated patients. 
Conversely, infarction occurred more often in patients with antihyper-
tensive treatment (32/80 patients (40%) versus 14/54 (26%) without anti-
hypertensives (p = 0.03)). This relationship was partly explained by co-
existing hyponatremia. 
Our results suggest that hypertension immediately after SAH may be a 
compensatory phenomenon and can be left untreated, since the prevention of 
rebleeding is offset by an increased risk of cerebral infarction. 
Acute hydrocephalus, detected by measuring the width of the lateral 
ventricles on the admission CT, was found to be associated with the 
development of hyponatremia. A possible explanation was that enlargement 
of the third ventricle might interfere with hypothalamic function, which in 
turn might cause hyponatremia. This possibility was explored in the study 
described in Chapter V. We investigated if the development of hyponatre-
mia was related to enlargement of the third ventricle on the admission CT 
scan, in a consecutive series of 133 patients who were seen within 72 hours of 
aneurysmal hemorrhage. Hyponatremia occurred significantly more often in 
patients with initial enlargement of the third and lateral ventricles than in 
patients with a normal ventricular system (12/26 versus 22/29, p = 0.05) and 
also in patients with enlargement of the third ventricle only (8/15, p = 0.03). 
The relationship between initial enlargement of the third ventricle and 
hyponatremia remained after adjustment for the amount of cisternal blood or 
for mild degrees of hyponatremia, but not entirely after adjustment for the 
amount of intraventricular blood. During the actual period of hyponatre-
mia, the association with the size of the third ventricle persisted. After 
ventricular drainage, the sodium levels returned to normal in two patients in 
whom the size of the third ventricle decreased, and not in four patients with 
persistent enlargement of the third ventricle. 
These results suggest that the size of the third ventricle is an important 
factor in the relationship between. acute hydrocephalus and hyponatremia, 
possibly mediated by pressure on the hypothalamus. 
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Chapter VI describes the study in which it was investigated if a natriuretic 
factor circulates after SAH. Digoxin-like substances have been found to 
possess natriuretic properties by inhibiting sodium transport in the kidney 
and enhancing sodium excretion. This substance can be demonstrated by a 
radioimmunoassay. 
After heating the plasma samples, an endogenous substance cross-reacting 
with antibodies to digoxin was identified in 18 of25 patients with SAH. The 
presence of this substance was significantly associated with an extensive 
hemorrhage and with a distribution of blood suggesting a ruptured anterior 
cerebral artery aneurysm, and could not be explained by other factors which 
are known to be associated with the presence of this substance in plasma, such 
as hypertension or fluid and salt loading. A negative sodium balance and 
volume depletion occurred more often in patients with a positive test for 
digoxin, but this relationship did not reach statistical significance. The 
conclusion is that a digoxin-like natriuretic substance is released in response 
to a subarachnoid hemorrhage, probably by hypothalamic damage. 
In the last chapter (VII) the results with fludrocortisone acetate treatment 
are presented. Fludrocortisone acetate has a mineralocorticoid action and 
enhances sodium absorption in the kidney. In a consecutive series of 39 
patients with CT evidence of subarachnoid hemorrhage, fludrocortisone 
acetate treatment was started on admission. In 28 patients an aneurysm was 
proved or probable, and in 21 of these the effect of fludrocortisone acetate on 
sodium balance and plasma volume could be studied. The plasma volume 
decreased more than 10% in four of the 21 patients, decreased less than 10% in 
five, and increased in 12 patients. The cumulative sodium balance measured 
over five days was negative in seven of the 21 patients, including three of the 
four patients with a substantial decrease in plasma volume. Plasma renin 
values were measured in 15 patients and were less high than in 18 previous 
patients not treated with fludrocortisone acetate, regardless of the presence of 
a negative sodium balance. Permanent side effects did not occur. In three of 
the 39 patients signs of pulmonary edema developed, and low serum 
potassium values were observed in four of the 21 patients. In comparison with 
previous studies, these findings sue-gest that fludrocortisone acetate is a 
comparatively safe and effective method of decreasing the incidence of 
volume depletion and negative sodium balance. 
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SAMENVATTING 
In dit proefschrift werd onderzocht waardoor patienten met een subarach-
no!dale bloeding (SAB) die tevens een hyponatriemie ontwikkeiden een 
slechte afloop hadden. Verder werden de oorzaken van een hyponatriemie 
onderzocht en werd nagegaan hoe een hyponatriemie kon worden voorko-
men. 
In het eerste hoofdstuk worden het natuurlijk beioop en de complicaties 
van een SAB beschreven. De incidentie van een SAB door een gebarsten 
aneurysma ligt tussen de 11 en 19 per 100.000 inwoners per jaar. Het is een 
ernstige aandoening met een hoge mortaliteit en morbiditeit. Ongeveer een 
derde van de patienten overlijdt of wordt ernstig ge!nvalideerd als direct 
gevolg van de bloeding. Deze groep patienten heeft waarschijn1ijk geen baat 
meer bij behandeling. Wei wordt verondersteid dat vele van deze ernstige en 
massale bloedingen worden voorafgegaan door kleine "waarschuwingsbloe-
dingen". Daarom is het mogelijk dat een groot gedeeite van deze patienten 
gered kan worden door deze waarschuwingsbloedingen tijdig te herkennen. 
De heift van de patienten die in een goede klinische toestand wordt 
opgenomen overlijdt of raakt ernstig gehandicapt door complicaties, die met 
name in de eerste weken na de bloeding optreden. De behandeiing is er dus 
op gericht deze ernstige complicaties te voorkomen. 
De neurologische complicaties worden in het tweede gedeeite van 
hoofdstuk I besproken. De afloop na een SAB wordt in beiangrijke mate 
be!nvloed door twee factoren, de recidiefbloeding en het herseninfarct. De 
afloop van de patienten die een recidiefbloeding krijgen is slecht, aangezien 
85% binnen drie maanden overlijdt. De frequentie van de recidiefbloeding is 
het hoogst aan het einde van de tweede en derde week na opneming en 
mogelijk zeifs op de eerste dag van de bloeding. Afklemmen van het 
aneurysma voorkomt het recidief Er bestaan verschillende meningen over 
het tijdstip van opera tie- binnen drie dagen of op een later tijdstip- en over 
weike patienten wei dan wei niet moeten worden geopereerd. 
Behandeiing met antifibrinolytica (tranexaminezuur) doet de kans op een 
recidiefbloeding aanzienlijk verminderen, maar de uiteindeiijke afloop 
verbetert niet, door een geiijktijdige toename van het aantal herseninfarcten. 
Dus is antifibrinolytische therapie niet zinvol, tenzij hersenischemie kan 
worden voorkomen. 
Bij ongeveer 27% van de patienten ontstaat er hersenischemie. Deze 
ischemie ontwikkelt zich geleidelijk en treedt met name op in de corticale en 
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waterscheidingsgebieden. Meestal krijgen de patienten focale uitvalver-
schijnselen, maar een daling van het bewustzijn kan eraan voorafgaan. Soms 
is dit het enige verschijnsel. Van de vele therapeutische maatregelen die zijn 
geprobeerd, lijken volume-expansie en bloeddrukverhoging een gunstig 
effect te hebben. 
Bij patienten die vroeg na de bloeding worden opgenomen treedt in 20% 
een acute hydrocephalus op. Het bewustzijnsniveau verbetert indrukwek-
kend na een liquor-afleidende ingreep, maar desondanks overlijdt een hoog 
percentage aan recidiefbloedingen en herseninfarcten. Mogelijk kan de 
afloop verbeterd worden door meer voorzichtige drainagetechnieken. 
De interne complicaties worden beschreven in het 3e gedeelte. Na 
subarachnoi:dale bloedingen worden vaak ECG-afwijkingen en een verho-
ging van de hartenzymen in het bloed waargenomen. Dit is het gevolg van 
een diffuse myofibrillaire degeneratie. Maar desondanks zijn ademhalings-
stoornissen veel frequenter dan hartritmestoornissen. Een bekende en 
dramatische complicatie is het neurogene longoedeem, maar gelukkig is de 
mortaliteit van deze complicatie gedaald door de invoering van positieve-
druk-beademing (PEEP). 
Hypertensie is vaak aanwezig bij patienten met een subarachnoi:dale 
bloeding, ook bi} die patienten die geen hypertensie in de voorgeschiedenis 
hebben. De behandeling van hypertensie direct na de bloeding vormt een 
belangrijk dilemma. Hypertensie kan de recidiefkans vergroten en herseni-
schemie bevorderen door de vorming van oedeem. Anderzijds kan verlagen 
van de bloeddruk leiden tot hersenischemie door verslechtering van de 
cerebrale perfusie. Minder voorkomende complicaties zijn gastro-intestinale 
bloedingen, sepsis en hyperglykemie. 
In het vierde gedeelte van hoofdstuk I worden de zouthuishouding en de 
oorzaken van een hyponatriemie besproken. Oorspronkelijk werd hypona-
triemie na een subarachnoi:dale bloeding geweten aan zoutverlies door een 
natriuretisch hormoon, het cerebrale zoutverlies-syndroom. Later werd het 
beschouwd als een uiting van een "inappropriate antidiuretisch hormoon-
secretie syndroom" (SIADH). Bij een SIADH werken de osmoreceptoren 
verhoudingsgewijs te sterk, hetgeen leidt tot een blijvend toegenomen 
uitscheiding van het antidiuretisch hormoon. Vervolgens leidt dit weer tot 
een toename van de extracellulaire ruimte, hyponatriemie en toegenomen 
zoutuitscheiding in de urine. Vochtbeperking wordt dus toegepast om deze 
verdunnings-hyponatriemie te bestrijden. Vochtbeperking kan schadelijk 
zijn als hyponatriemie samengaat met een verlaagd intravasculair volume, 
omdat vochtbeperking dan kan leiden tot hemoconcentratie en verande-
ringen in de viscositeit vanhet bloed. Met name is dit gevaarlijk bij patienten 
met vaatspasme en een daardoor al beperkte cerebrale perfusie. Het is te 
verwachten dat als hyponatriemie samengaat met een laag plasmavolume, 
patienten met een hyponatriemie en vochtbeperking een hogere kans op 
herseninfarcten hebben. Vandaar dat we de relatie tussen hyponatriemie en 
herseninfarcten onderzoch ten. 
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De resultaten hiervan worden beschreven in hoofdstuk II. In een groep van 
134 opeenvolgende patienten met een SAB hadden 44 patienten serum-
natriumwaarden onder de 135 mmol per liter gedurende ten minste twee 
opeenvolgende dagen. Hyponatriemie ontwikkelde zich tussen de 2e en de 
lOe dag na de bloeding. Ernstige hyponatriemie (natriumwaarden van 120 
tot 124 mmol/L) werd bij slechts 6 van deze 44 patienten waargenomen. Vijf-
entwintig van de 44 patienten voldeden aan de laboratoriumcriteria voor 
SIADH. Bij 12 waren er andere omstandigheden die hyponatriemie konden 
veroorzaken (sepsis, veel braken, nierziekte, ziekte van Addison en diure-
tica). Bij 7 patienten bleef de oorz,aak onbekend door onvolledige labora-
toriumgegevens. Het voorkomen van de herseninfarcten, vaak met letale 
afloop, was significant hoger bij patienten die een hyponatriemie ontwik-
kelden. De klinische achteruitgang kon niet aan de hyponatriemie worden 
toegeschreven, maar bleek enkele dagen later te berusten op een zich 
ontwikkeld herseninfarct. 
Zesentwintig van de 44 patienten met een hyponatriemie werden 
behandeld met vochtbeperking, en bij 21 ontstonden er herseninfarcten. Het 
lijkt dat de correctie van hyponatriemie door het geven van vochtbeperking 
gevaarlijk is bij patienten met een SAB. Daarnaast ondersteunt dit de 
veronderstelling dat hyponatriemie door zoutverlies wordt veroorzaakt. 
Het onderzoek in hoofdstuk III gaat na ofhyponatriemie na een subarach-
no'idale bloeding veroorzaakt wordt door een verdunningshyponatriemie of 
door een primair zoutverlies. Bij 21 patienten met een subarachno'idale 
bloeding door een gebarsten intracranieel aneurysma werd een prospectieve 
studie verricht naar veranderingen in het plasmavolume, de zoutbalans en 
naar de secretie van het antidiuretisch hormoon (vasopressine). Bij ll van de 
21 patienten daalde het plasmavolume, gemeten met een isotoop-verdun-
ningstechniek, met meer dan l 0%. Dit ging gepaard met een negatieve 
zoutbalans en hyponatriemie bij zes patienten, een negatieve zoutbalans 
zonder hyponatriemie bij vier, en een positieve zoutbalans bij een patient. 
Tevens steeg het ureumgehalte in het bloed en daalde het lichaamsgewicht. 
De vasopressinewaarden in het serum waren verhoogd bij opneming en 
daalden bij alle patienten in de eerste week, ongeacht de aanwezigheid van 
h ypona triemie. 
Deze bevindingen wijzen erop dat er sprake is van een zoutverlies-
syndroom en niet van een SIADH. Deze studie toonde aan dat patienten met 
een SAB dus een volumedepletie en natriurese hebben en met volume-
expansie behoren te worden behandeld. Het instandhouden van een 
adequaat intravasculair volume is belangrijk bij de behandeling van 
patienten met een SAB. Patienten met een SAB worden bedreigd door 
vaatspasme wat tot hersenischemie kan leiden als de cerebrale bloeddoor-
stroming verder verslechtert door volumedepletie. De doeltreffendheid van 
volume-expansie bij het vergroten van de cerebrale perfusie kan dan 
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verklaard worden door een verhoging van de viscositeit van het bloed of door 
een stijging van het hartminutenvolume, hetgeen nog waarschijnlijker wordt 
door onderzoekingen die verbetering van uitvalverschijnselen ten gevolge 
van hersenischemie lieten zien tijdens volume-expansie. 
Het verhogen van de bloedddruk is een andere manier om hersenischemie 
te voorkomen, wat door verschillende onderzoekers werd aangetoond. Dit 
kan betekenen dat hoge bloeddruk na een SAB hersenischemie voork6mt en 
dus niet met antihypertensiva moet worden behandeld. Echter, als een hoge 
bloeddruk wordt geaccepteerd kan dit een verhoogde recidiefkans tot gevolg 
hebben. 
We onderzochten of behandeling van een hoge bloeddruk verband hield 
met het v66rkomen van herseninfarcten en recidiefbloedingen (hoofstuk IV). 
Het doel was de diastolische bloeddruk te verlagen tot onder 110 mm Hg. De 
uiteindelijke afloop bij patienten met en zonder antihypertensiva bleek niet 
verschillend te zijn. Recidiefbloedingen kwamen minder vaak voor bij 
patienten na een antihypertensieve behandeling dan bij patienten zonder 
antihypertensiva (12 van 80 patienten (15%) versus 18/54 (33%) (p =0.012)). 
Patienten met antihypertensieve behandeling hadden gemiddeld toch nog 
een hogere bloeddruk dan onbehandelde patienten. Daarentegen kwamen 
herseninfarcten vaker voor bij patienten met antihypertensieve behandeling 
(32/80 (40%) versus 14/54 (26%) (p = 0.03)). Deze associatie kon maar ten 
dele verklaard worden door een gelijktijdig aanwezige hyponatriemie. De 
conclusie luidt dat hypertensie na een SAB een compensatoir mechanisme is 
en niet moet worden behandeld, aangezien preventie van recidiefbloedingen 
door een toegenomen frequentie van herseninfarcten wordt tenietgedaan. 
Hyponatriemie was gecorreleerd met de aanwezigheid van een acute 
hydrocephalus op de CT-scan bij opneming. Dit kon mogelijk verklaard 
worden door een vergroting van de derde ventrikel. Druk op de hypothala-
mus zou dan vervolgens kunnen leiden tot hyponatriemie. Dit werd onder-
zocht in een studie beschreven in hoofdstuk V. Hyponatriemie kwam 
significant vaker voor bij patienten met een vergroting van de derde ventrikel 
en de zijventrikels dan bij patienten met een normaal ventrikelsysteem, maar 
ook bij patienten met vergroting van aileen de derde ventrikel. Deze 
correlatie bleef bestaan na correctie voor de hoeveelheid subarachnoi:daal 
bloed, maar niet geheel na correctie voor de h<?eveelheid intraventriculair 
bloed. Echter, de bijdrage van intraventriculair bloed is klein en het 
belangrijkste effect van intraventriculair bloed is dat het een vergroting van 
de derde ventrikel veroor:zaakt, gevolgd door een hyponatriemie. 
Welke cerebrale factor hyponatriemie veroorzaakt is onbekend, maar deze 
resultaten wijzen erop dat uitzetting van de derde ventrikel een belangrijke 
factor is, mogelijk door druk op de hypothalamus en daardoor vrijkomen van 
een natriuretische factor. 
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Of een dergelijke factor aanwezig is bij een SAB werd onderzocht in een 
studie beschreven in hoofdstuk VI. Digoxine-achtige substanties blijken 
natriuretische eigenschappen te hebben doordat ze het natriumtransport in 
denier tegengaan. Een dergelijke substantie kan worden aangetoond door 
een radioimmunoassay. 
Bij 18 van 25 patienten met een SAB kon na verhitten van het plasma een 
endogene substantie worden aangetoond die reageerde met antilichamen 
tegen digoxine. De aanwezigheid van deze substantie was significant 
gerelateerd aan de ernst van de bloeding en aan een verdeling van het bloed 
op de CT-scan passend bij een gebarsten aneurysma van de arteria cerebri 
communicans anterior. Er was geen relatie met andere factoren zoals 
hypertensie of vocht- en zoutbelasting. De aanwezigheid van deze digoxine-
achtige substantie kwam vaker voor bij patienten met een negatieve 
zoutbalans en een daling van het plasma volume; het verschil was echter niet 
statistisch significant. De conclusie is dat een op digoxine gelijkende 
substantie vrijkomt na een subarachnoi"dale bloeding, mogelijk door bescha-
diging van de hypothalamus. 
De behandeling met fludrocortisonacetaat wordt beschreven in het laatste 
hoofdstuk (VII). Doordat fludrocortisonacetaat mineralocorticoi"de eigen-
schappen heeft vergroot deze stof de natriumabsorptie in de nier. In een 
proefonderzoek naar het effect van fludrocortisonacetaat op de zoutbalans en 
het plasmavolume bij 21 patienten met een SAB, daalde het plasmavolume 
maar bij slechts vier patienten (19%) meer dan 10%. Een negatieve zout-
balans werd bij zeven van de 21 patienten (33%) gevonden. Deze waarden 
werden vergeleken met de resultaten uit hoofdstuk III, waarbij 52% van de 
patienten een daling van het plasma volume van meer dan l 0% toonde en 67% 
van de patienten een negatieve zoutbalans had. Hieruit kan met enig 
voorbehoud worden geconcludeerd dat fludrocortisonacetaat een effect heeft 
op het plasma volume en de zoutuitscheiding. Bovendien waren in het plasma 
de reninewaarden bij de behandelde patienten lager dan bij de onbehan-
delde patienten met een negatieve zoutbalans uit hoofdstuk IlL Complica-
ties, zoals hypokaliemie en -longoedeem door overvulling waren weinig 
frequent en makkelijk behandelbaar. Hieruit kan worden geconcludeerd dat 
fludrocortisonacetaat een nuttige en vooral veilige manier is om daling van 
het plasmavolume en waarschijnlijk het ontstaan van een negatieve zout-
balans bij SAB te voorkomen. 
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